Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

CSTL

Castle Biosciences Inc

May 03 • 04:00PM ET

24.33

Dollar change +1.49
Percentage change 6.52	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWN SCHA DFAT VTWO VHT IWO

Index	RUT	P/E	-	EPS (ttm)	-1.15	Insider Own	6.69%	Shs Outstand	27.41M	Perf Week	19.62%
Market Cap	671.75M	Forward P/E	-	EPS next Y	-1.95	Insider Trans	-14.67%	Shs Float	25.76M	Perf Month	14.55%
Income	-30.80M	PEG	-	EPS next Q	-0.35	Inst Own	82.80%	Short Float	5.66%	Perf Quarter	3.93%
Sales	250.72M	P/S	2.68	EPS this Y	26.09%	Inst Trans	-2.02%	Short Ratio	6.23	Perf Half Y	54.97%
Book/sh	14.59	P/B	1.67	EPS next Y	-23.58%	ROA	-6.96%	Short Interest	1.46M	Perf Year	6.20%
Cash/sh	8.66	P/C	2.81	EPS next 5Y	-	ROE	-7.82%	52W Range	9.26 - 26.70	Perf YTD	12.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.57%	ROI	-7.22%	52W High	-8.88%	Beta	0.93
Dividend TTM	-	Quick Ratio	9.02	Sales past 5Y	60.93%	Gross Margin	76.33%	52W Low	162.74%	ATR (14)	1.17
Dividend Ex-Date	-	Current Ratio	9.25	EPS Y/Y TTM	57.68%	Oper. Margin	-16.72%	RSI (14)	70.07	Volatility	7.05% 4.68%
Employees	610	Debt/Eq	0.06	Sales Y/Y TTM	64.71%	Profit Margin	-12.28%	Recom	1.11	Target Price	34.33
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	91.60%	Payout	-	Rel Volume	3.59	Prev Close	22.84
Sales Surprise	7.17%	EPS Surprise	72.89%	Sales Q/Q	73.59%	Earnings	May 02 AMC	Avg Volume	234.05K	Price	24.33
SMA20	19.60%	SMA50	16.44%	SMA200	26.45%	Trades		Volume	839,813	Change	6.52%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Buy	$25
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$54
Jan-07-22	Initiated	Stephens	Overweight	$59
Apr-30-21	Initiated	Lake Street	Buy	$94
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$70
Dec-27-19	Reiterated	Canaccord Genuity	Buy	$34 → $35
Aug-19-19	Initiated	SVB Leerink	Outperform	$28
Aug-19-19	Initiated	Robert W. Baird	Outperform	$27
Aug-19-19	Initiated	Canaccord Genuity	Buy	$26
Aug-19-19	Initiated	BTIG Research	Buy	$25

May-03-24 07:00AM	DecisionDx-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck (Business Wire) +6.52%
May-02-24 08:56PM	CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:59PM	Castle Biosciences Inc (CSTL) Q1 2024 Earnings: Surpasses Revenue Forecasts and Raises Annual ... (GuruFocus.com)
05:50PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports First Quarter 2024 Results (Business Wire)
04:30PM	Loading…
Apr-30-24 04:30PM	Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswoods Designation as a Sun Safe Leadership Model City by IMPACT Melanoma (Business Wire)
Apr-11-24 07:00AM	Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 (Business Wire)
Apr-10-24 05:00PM	Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations (Business Wire) -5.15%
07:00AM	Castle Biosciences Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year (Business Wire)
Apr-05-24 04:43AM	What Makes Castle Bioscience (CSTL) a Prospective Investment? (Insider Monkey)
Apr-04-24 04:30PM	Presentations at EADO Highlight Potential Impact of Castle Biosciences DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer (Business Wire)
Apr-02-24 07:00AM	Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-27-24 05:00PM	Castle Biosciences Announces Updates to its Board of Directors (Business Wire)
Mar-25-24 07:00AM	Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year (Business Wire)
Mar-22-24 04:30PM	Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB (Business Wire)
05:17AM	Loading…
Mar-20-24 05:17AM	Does Castle Bioscience (CSTL) Have Robust Growth Prospects? (Insider Monkey) +5.11%
Mar-19-24 07:00AM	Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy (Business Wire)
Mar-15-24 04:30PM	New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences IDgenetix Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older (Business Wire)
Mar-12-24 07:00AM	Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum (Business Wire)
Mar-08-24 04:30PM	Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-07-24 07:00AM	In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups (Business Wire)
Feb-29-24 10:37AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Call Transcript (Insider Monkey) -25.95%
08:43AM	Q4 2023 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-24 06:30PM	Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:40PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Castle Biosciences Inc (CSTL) Reports Robust Revenue Growth and Improved Margins in 2023 (GuruFocus.com)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results (Business Wire)
Feb-26-24 09:16AM	Insights Into Castle Biosciences, Inc. (CSTL) Q4: Wall Street Projections for Key Metrics (Zacks)
07:00AM	Study Finds DecisionDx-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging (Business Wire)
Feb-07-24 07:00AM	Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024 (Business Wire)
07:00AM	Loading…
Jan-18-24 07:00AM	New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences DecisionDx-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma (Business Wire)
Jan-14-24 04:30AM	Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii (Business Wire)
Jan-09-24 07:00AM	Castle Biosciences Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report (Business Wire)
Jan-07-24 08:00PM	Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results (Business Wire)
Dec-20-23 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-12-23 09:55AM	How Much Upside is Left in Castle Biosciences, Inc. (CSTL)? Wall Street Analysts Think 67.01% (Zacks)
Dec-01-23 07:00AM	Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx-Melanoma Test Results (Business Wire)
Nov-14-23 07:00AM	Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting (Business Wire) +8.01%
Nov-13-23 07:00AM	Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year (Business Wire)
Nov-08-23 04:30PM	Real-World Evidence Confirms IDgenetix-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder (Business Wire)
01:00PM	Castle Biosciences to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-23 09:18AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:11AM	Q3 2023 Castle Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +7.99%
07:00AM	Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx-UM That Could Aid in the Early Detection of Uveal Melanomas (Business Wire)
Nov-02-23 07:30PM	Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings (Zacks) +6.05%
07:24PM	Castle Biosciences Inc (CSTL) Reports 66% Revenue Increase in Q3 2023 (GuruFocus.com)
04:06PM	Early Discovery Data Shows Ability of Castle Biosciences Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy (Business Wire)
04:05PM	Castle Biosciences Reports Third Quarter 2023 Results (Business Wire)
Oct-24-23 07:00AM	Castle Biosciences to Present New Data on its TissueCypher Barretts Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting (Business Wire)
Oct-19-23 07:00AM	Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2 (Business Wire)
Oct-18-23 04:30PM	New Data Highlights Clinical Utility and Performance of Castle Biosciences Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference (Business Wire)
Oct-05-23 07:00AM	DecisionDx-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma (Business Wire)
Oct-03-23 07:00AM	Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy (Business Wire)
Oct-02-23 07:00AM	Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barretts Esophagus (Business Wire)
Sep-25-23 07:00AM	Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma (Business Wire)
Sep-19-23 07:00AM	Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry (Business Wire)
Sep-14-23 07:00AM	TissueCypher® Barretts Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barretts Esophagus (Business Wire)
Sep-12-23 07:00AM	Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory (Business Wire)
Sep-09-23 08:00PM	Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression (Business Wire)
Sep-08-23 04:30PM	TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barretts Esophagus (Business Wire)
Sep-06-23 07:00AM	Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023 (Business Wire)
Sep-05-23 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Aug-07-23 07:00AM	New Publication Highlights the Ability of the TissueCypher® Barretts Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barretts Esophagus (Business Wire)
Aug-03-23 11:17AM	Why Castle Biosciences Stock Is Jumping Today (Motley Fool) +11.79%
08:31AM	Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-02-23 07:30PM	Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings (Zacks)
06:15PM	Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports Second Quarter 2023 Results (Business Wire)
Aug-01-23 07:00AM	Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-26-23 10:02AM	Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline (Zacks)
Jul-19-23 07:00AM	Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2 (Business Wire)
Jul-18-23 07:00AM	Castle Biosciences to Host Second Annual Castle Cares Charity Walk (Business Wire)
Jul-17-23 07:00AM	Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year (Business Wire)
Jul-13-23 05:18PM	Why Shares of Castle Biosciences Fell This Week (Motley Fool) -9.65%
Jul-07-23 12:16PM	Why Castle Biosciences Stock Is Crushing It Today (Motley Fool) +52.86%
12:14PM	First Solar, Castle Biosciences rise; Levi Strauss falls, Friday, 7/7/2023 (AP Finance)
07:00AM	Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Societys (AHNS) 11th International Conference on Head and Neck Cancer (Business Wire)
Jun-30-23 07:00AM	Study Data from Castle Biosciences Collaboration with the National Cancer Institutes SEER Program Registries Published in JCO Precision Oncology (Business Wire)
Jun-21-23 09:58AM	Down More Than 40%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound (TipRanks)
Jun-20-23 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-12-23 07:00AM	Castle Biosciences Presents New Data Demonstrating the Ability of DecisionDx®-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging (Business Wire)
Jun-11-23 08:04AM	Castle Biosciences Independent Director Acquires 113% More Stock \ (Simply Wall St.)
Jun-08-23 06:34AM	Benign Growth For Castle Biosciences, Inc. (NASDAQ:CSTL) Underpins Stock's 34% Plummet (Simply Wall St.)
Jun-05-23 03:04PM	Why Shares of Castle Biosciences Plummeted on Monday (Motley Fool) -48.70%
07:00AM	Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology (Business Wire)
Jun-03-23 07:00AM	Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting (Business Wire)
Jun-02-23 05:04PM	Why Shares of Castle Biosciences Slumped This Week (Motley Fool) +7.98%
May-31-23 07:00AM	IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder (Business Wire)
May-30-23 07:00AM	Castle Biosciences Celebrates Skin Cancer Awareness Month (Business Wire) -5.31%
May-26-23 07:00AM	Castle Biosciences Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as "Posters of Distinction" by the American Gastroenterological Association (AGA) Institute Council (Business Wire)
May-24-23 07:07PM	First look: Castle Biosciences celebrates grand opening of 20,000-square-foot lab in Nova Place (American City Business Journals)
07:07PM	Castle Biosciences celebrates grand opening of 20,000-square-foot lab in Nova Place (American City Business Journals)
May-22-23 07:00AM	Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh (Business Wire)
May-15-23 07:00AM	Castle Biosciences TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation (Business Wire)
May-05-23 06:21AM	Castle Biosciences First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-03-23 05:45PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Castle Biosciences Reports First Quarter 2023 Results (Business Wire)
07:00AM	Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies (Business Wire)
Apr-28-23 07:00AM	Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event (Business Wire)
Apr-25-23 07:00AM	DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients (Business Wire)

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 23 '24	Sale	20.11	705	14,177	9,683	Apr 25 04:54 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 23 '24	Sale	20.11	421	8,466	64,997	Apr 25 04:54 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 12 '24	Sale	20.35	3,263	66,402	9,752	Apr 16 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 12 '24	Sale	20.35	1,947	39,621	65,418	Apr 16 04:46 PM
BRADBURY DANIEL	Director	Apr 08 '24	Sale	20.45	2,400	49,087	17,944	Apr 10 04:35 PM
BRADBURY DANIEL	Director	Apr 05 '24	Sale	20.86	11,771	245,543	18,763	Apr 08 04:31 PM
BRADBURY DANIEL	Director	Apr 04 '24	Sale	21.45	9,152	196,310	22,782	Apr 08 04:31 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 03 '24	Sale	21.70	3,968	86,106	10,069	Apr 05 04:37 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 03 '24	Sale	21.70	2,368	51,386	67,365	Apr 05 04:37 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 21 '24	Sale	20.70	121	2,505	10,455	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 21 '24	Sale	20.70	73	1,511	69,733	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 20 '24	Sale	20.27	3,847	77,979	10,467	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 20 '24	Sale	20.27	2,295	46,520	69,806	Mar 22 05:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '24	Sale	20.77	3,996	82,997	10,841	Mar 11 05:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 07 '24	Sale	20.77	2,372	49,266	72,101	Mar 11 05:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 05 '24	Option Exercise	3.72	10,686	39,752	78,604	Mar 06 05:58 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Mar 05 '24	Sale	21.41	4,131	88,461	74,473	Mar 06 05:58 PM
BRADBURY DANIEL	Director	Mar 04 '24	Sale	20.68	23,323	482,285	25,907	Mar 06 05:52 PM
BRADBURY DANIEL	Director	Feb 07 '24	Sale	23.20	2,074	48,117	33,870	Feb 09 04:49 PM
BRADBURY DANIEL	Director	Feb 06 '24	Sale	23.63	9,847	232,685	34,578	Feb 07 04:19 PM
BRADBURY DANIEL	Director	Feb 05 '24	Sale	22.90	11,402	261,134	37,940	Feb 07 04:19 PM
BRADBURY DANIEL	Director	Jan 05 '24	Sale	20.36	5,100	103,836	41,833	Jan 08 04:19 PM
BRADBURY DANIEL	Director	Jan 04 '24	Sale	20.40	18,223	371,749	43,574	Jan 08 04:19 PM
Juvenal Tobin W	Chief Commercial Officer	Jan 02 '24	Option Exercise	2.89	6,701	19,381	46,857	Jan 04 05:16 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 29 '23	Option Exercise	3.01	12,615	38,034	150,302	Jan 03 04:11 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 28 '23	Sale	22.17	3,954	87,660	64,084	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 28 '23	Sale	22.17	557	12,349	11,629	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 27 '23	Sale	21.90	8,076	176,864	68,038	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 27 '23	Sale	21.90	1,137	24,900	11,688	Dec 29 04:05 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 26 '23	Sale	21.93	5,180	113,597	76,114	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 26 '23	Sale	21.93	729	15,987	11,807	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '23	Sale	21.96	5,224	114,719	81,294	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 22 '23	Sale	21.96	736	16,163	11,884	Dec 27 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 21 '23	Sale	21.40	10,999	235,412	86,518	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 21 '23	Sale	21.40	1,549	33,153	11,962	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 20 '23	Sale	21.05	5,201	109,455	97,517	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 20 '23	Sale	21.05	733	15,426	12,125	Dec 22 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 19 '23	Sale	20.84	5,719	119,161	102,718	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 19 '23	Sale	20.84	3,314	69,051	12,202	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 18 '23	Sale	20.27	5,720	115,962	108,437	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 18 '23	Sale	20.27	1,498	30,369	12,552	Dec 20 04:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '23	Sale	20.21	3,709	74,959	114,157	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 15 '23	Sale	20.21	1,113	22,494	12,710	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 14 '23	Sale	20.89	9,976	208,363	12,827	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 14 '23	Sale	20.89	9,152	191,151	117,866	Dec 18 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '23	Sale	20.21	3,980	80,436	13,879	Dec 14 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 13 '23	Sale	20.21	3,652	73,807	127,018	Dec 14 05:39 PM
BRADBURY DANIEL	Director	Dec 13 '23	Sale	20.04	1,168	23,407	49,796	Dec 14 05:32 PM
BRADBURY DANIEL	Director	Dec 12 '23	Sale	20.01	1,200	24,012	50,195	Dec 14 05:32 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 12 '23	Sale	20.01	546	10,925	130,670	Dec 14 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 12 '23	Sale	20.01	254	5,083	14,298	Dec 14 05:39 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 10 '23	Option Exercise	0.00	7,920	0	138,149	Dec 12 07:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 10 '23	Option Exercise	0.00	20,787	0	133,327	Dec 12 07:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 09 '23	Option Exercise	0.00	33,496	0	128,391	Dec 12 07:23 PM
Oelschlager Kristen M	Chief Operating Officer	Dec 09 '23	Option Exercise	0.00	15,961	0	136,061	Dec 12 07:39 PM
BRADBURY DANIEL	Director	Dec 08 '23	Sale	20.09	6,875	138,119	50,605	Dec 12 07:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 08 '23	Sale	20.10	2,530	50,853	14,325	Dec 12 07:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 08 '23	Sale	20.10	2,322	46,672	94,895	Dec 12 07:23 PM
BRADBURY DANIEL	Director	Dec 06 '23	Sale	20.02	200	4,004	52,952	Dec 08 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 06 '23	Sale	20.02	52	1,041	14,592	Dec 08 04:38 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 06 '23	Sale	20.02	48	961	97,217	Dec 08 04:38 PM
BRADBURY DANIEL	Director	Dec 04 '23	Sale	20.08	4,340	87,165	53,020	Dec 05 05:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '23	Sale	20.08	1,504	30,200	14,597	Dec 05 05:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 04 '23	Sale	20.08	1,379	27,690	97,265	Dec 05 05:49 PM
BRADBURY DANIEL	Director	Dec 01 '23	Sale	20.05	9,545	191,425	54,502	Dec 05 05:46 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 01 '23	Sale	20.06	3,526	70,732	14,756	Dec 05 05:49 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Dec 01 '23	Sale	20.06	3,235	64,894	98,644	Dec 05 05:49 PM
BRADBURY DANIEL	Director	Nov 30 '23	Sale	20.08	12,179	244,566	57,761	Dec 01 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 30 '23	Sale	20.07	4,915	98,644	15,127	Dec 01 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 30 '23	Sale	20.07	4,510	90,516	101,879	Dec 01 04:34 PM
BRADBURY DANIEL	Director	Nov 29 '23	Sale	20.12	17,342	349,008	60,197	Dec 01 04:30 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 29 '23	Sale	20.13	6,261	126,034	15,645	Dec 01 04:34 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 29 '23	Sale	20.13	5,743	115,607	106,389	Dec 01 04:34 PM
BRADBURY DANIEL	Director	Nov 24 '23	Sale	20.02	800	16,016	63,665	Nov 28 04:31 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 24 '23	Sale	20.03	313	6,269	16,305	Nov 28 04:43 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 24 '23	Sale	20.03	287	5,749	112,132	Nov 28 04:43 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 21 '23	Sale	20.01	826	16,528	16,338	Nov 22 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 21 '23	Sale	20.01	758	15,168	112,419	Nov 22 04:20 PM
BRADBURY DANIEL	Director	Nov 21 '23	Sale	20.00	300	6,000	63,825	Nov 22 04:22 PM
BRADBURY DANIEL	Director	Nov 20 '23	Sale	20.04	5,755	115,330	63,885	Nov 22 04:22 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 20 '23	Sale	20.04	2,100	42,084	16,425	Nov 22 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 20 '23	Sale	20.04	1,926	38,597	113,177	Nov 22 04:20 PM
BRADBURY DANIEL	Director	Sep 01 '23	Sale	20.04	1,802	36,112	65,037	Sep 06 04:28 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 01 '23	Sale	20.05	782	15,681	16,646	Sep 06 04:40 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 01 '23	Sale	20.05	718	14,397	115,103	Sep 06 04:40 PM
BRADBURY DANIEL	Director	Aug 31 '23	Sale	20.05	7,286	146,106	65,397	Sep 01 04:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 31 '23	Sale	20.06	4,471	89,679	16,729	Sep 01 04:26 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 31 '23	Sale	20.06	4,084	81,917	115,821	Sep 01 04:26 PM
BRADBURY DANIEL	Director	Aug 30 '23	Sale	20.03	4,632	92,779	66,854	Sep 01 04:23 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 30 '23	Sale	20.03	1,778	35,619	17,202	Sep 01 04:26 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 30 '23	Sale	20.03	1,622	32,494	119,905	Sep 01 04:26 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '23	Sale	20.10	314	6,311	17,391	Aug 07 05:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '23	Sale	20.10	286	5,749	121,527	Aug 07 05:07 PM
BRADBURY DANIEL	Director	Jul 07 '23	Sale	20.39	50,000	1,019,500	67,780	Jul 11 05:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 07 '23	Sale	20.04	16,740	335,537	17,424	Jul 11 05:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 07 '23	Sale	20.04	8,376	167,889	121,813	Jul 11 05:10 PM
Goldberg Ellen	Director	Jun 05 '23	Buy	14.38	4,800	69,004	9,065	Jun 06 04:48 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 16 '23	Sale	22.82	2,506	57,187	19,515	May 17 05:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 16 '23	Sale	22.82	1,254	28,616	149,189	May 17 05:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 15 '23	Sale	23.45	3,074	72,076	19,828	May 17 05:07 PM

Open in Screener

NTRA

Natera Inc

May 03 • 04:00PM ET

96.98

Dollar change +3.26
Percentage change 3.48	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VXF VBK IBB SCHA IWP FBT VHT IWF

Index	-	P/E	-	EPS (ttm)	-3.80	Insider Own	6.33%	Shs Outstand	119.58M	Perf Week	5.80%
Market Cap	11.85B	Forward P/E	-	EPS next Y	-1.19	Insider Trans	-15.59%	Shs Float	114.52M	Perf Month	5.00%
Income	-434.80M	PEG	-	EPS next Q	-0.71	Inst Own	91.44%	Short Float	5.03%	Perf Quarter	43.19%
Sales	1.08B	P/S	10.95	EPS this Y	38.74%	Inst Trans	1.75%	Short Ratio	4.20	Perf Half Y	144.34%
Book/sh	6.40	P/B	15.15	EPS next Y	48.70%	ROA	-30.28%	Short Interest	5.76M	Perf Year	86.00%
Cash/sh	7.19	P/C	13.49	EPS next 5Y	-	ROE	-59.11%	52W Range	36.90 - 98.82	Perf YTD	54.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.28%	ROI	-38.99%	52W High	-1.86%	Beta	1.50
Dividend TTM	-	Quick Ratio	3.96	Sales past 5Y	33.95%	Gross Margin	45.52%	52W Low	162.82%	ATR (14)	3.39
Dividend Ex-Date	-	Current Ratio	4.10	EPS Y/Y TTM	31.79%	Oper. Margin	-41.22%	RSI (14)	63.46	Volatility	3.56% 3.58%
Employees	3293	Debt/Eq	0.58	Sales Y/Y TTM	31.99%	Profit Margin	-40.16%	Recom	1.50	Target Price	103.89
Option/Short	Yes / Yes	LT Debt/Eq	0.46	EPS Q/Q	52.15%	Payout	-	Rel Volume	0.69	Prev Close	93.72
Sales Surprise	3.70%	EPS Surprise	15.57%	Sales Q/Q	43.20%	Earnings	May 09 AMC	Avg Volume	1.37M	Price	96.98
SMA20	4.85%	SMA50	8.21%	SMA200	53.56%	Trades		Volume	939,653	Change	3.48%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90
Jan-06-22	Resumed	Piper Sandler	Overweight	$110
Oct-15-21	Resumed	Cowen	Outperform	$150
Jun-15-21	Initiated	Raymond James	Mkt Perform
May-25-21	Initiated	Wells Fargo	Overweight	$110
Jan-28-21	Initiated	Truist	Buy	$143
Oct-08-20	Initiated	BTIG Research	Buy	$90
Sep-28-20	Initiated	Morgan Stanley	Overweight	$80

Show Previous Ratings

May-03-24 08:00AM	New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Breast Cancer (Business Wire)
May-02-24 02:14PM	NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:50AM	Insider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
02:49AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
May-01-24 04:05PM	Natera to Report its First Quarter 2024 Results on May 9 (Business Wire)
07:00AM	Loading…
07:00AM	Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage (Business Wire)
Apr-27-24 02:42AM	Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (GuruFocus.com)
Apr-26-24 06:32PM	10 Cathie Wood Stocks Insiders are Selling (Insider Monkey)
Apr-24-24 08:36AM	Natera (NTRA) Rose on Momentum in the Oncology Market (Insider Monkey)
02:38AM	Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
02:38AM	CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Apr-22-24 08:00AM	Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications (Business Wire)
Apr-18-24 02:05AM	Insider Sell: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Apr-17-24 08:31AM	TipRanks Perfect 10 List: Analysts See Opportunity in These 2 Top-Scoring Stocks (TipRanks)
Apr-11-24 08:00AM	Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation (Business Wire)
07:37AM	Loading…
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 08:00AM	Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients (Business Wire)
Apr-05-24 07:00AM	Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer (Business Wire)
05:15AM	Is Natera (NTRA) On The Cusp Of Being Cash Flow Positive? (Insider Monkey)
01:51AM	Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Apr-01-24 08:00AM	Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer (Business Wire)
Mar-21-24 10:25AM	11 Best Healthcare ETFs To Buy Now (Insider Monkey)
Mar-20-24 05:46AM	Will Natera (NTRA) Continue to Deliver Solid Topline Growth? (Insider Monkey)
Mar-18-24 03:39PM	Genetic Testing Stock Nears Buy Point After Earnings Gap-Up And 45% Gain (Investor's Business Daily)
07:00AM	Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera in Stage II Colorectal Cancer (Business Wire)
Mar-14-24 08:00AM	New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease (Business Wire)
Mar-12-24 08:00AM	Natera to Present New Data at the 2024 SGO Annual Meeting on Womens Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers (Business Wire)
Mar-11-24 02:22PM	Final Trades: Natera, Disney, Chubb and ASML Holding (CNBC TV)
Mar-08-24 01:31AM	SEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Mar-07-24 08:00AM	Natera Announces Commercial Coverage for Prospera Kidney and Prospera Heart from a Top BCBS Plan (Business Wire)
12:00PM	Loading…
Mar-04-24 12:00PM	What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-01-24 12:09AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Feb-29-24 11:06AM	Q4 2023 Natera Inc Earnings Call (Thomson Reuters StreetEvents) +12.98%
08:12AM	Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:00AM	Natera to Participate in March Investor Conferences (Business Wire)
Feb-28-24 06:30PM	Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics (Zacks)
04:32PM	Natera Inc (NTRA) Reports Significant Revenue Growth and Improved Gross Margins in Full Year 2023 (GuruFocus.com)
04:05PM	Natera Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-27-24 08:12AM	Natera (NTRA) Management Increased Full Year Guidance (Insider Monkey)
08:00AM	Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests (Business Wire)
01:07AM	Natera secures Medicare coverage for cancer test in 2 new indications (MedTech Dive)
Feb-26-24 07:00AM	Medicare Extends Coverage of Nateras Signatera MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer (Business Wire) +5.29%
Feb-20-24 08:00AM	Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call (Business Wire)
Feb-17-24 12:07AM	Natera Inc Director Herm Rosenman Sells 93,901 Shares (GuruFocus.com)
Feb-06-24 04:00PM	3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List (InvestorPlace)
Feb-05-24 08:00AM	New Study Validates Signatera in Endometrial Cancer (Business Wire)
Feb-02-24 11:02PM	Insider Sell: CFO Michael Brophy Sells 22,281 Shares of Natera Inc (GuruFocus.com)
Jan-31-24 05:02PM	Insider Sell: CFO Michael Brophy Sells 3,235 Shares of Natera Inc (GuruFocus.com)
Jan-30-24 09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (GlobeNewswire)
07:00AM	New Publication Demonstrates Signateras Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer (Business Wire)
Jan-29-24 07:00AM	Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties (Business Wire)
Jan-25-24 07:00AM	Nature Medicine Publishes Two Studies Highlighting Signateras Clinical Utility in Patients with Gastrointestinal Malignancies (Business Wire)
Jan-24-24 12:20AM	Insider Sell: CFO Michael Brophy Sells 2,973 Shares of Natera Inc (NTRA) (GuruFocus.com)
Jan-22-24 07:00AM	Natera Acquires Reproductive Health Assets from Invitae (Business Wire)
07:00AM	Invitae Completes Sale of Reproductive Health Assets to Natera (PR Newswire)
Jan-18-24 08:00AM	Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signateras Clinical Utility in CRC (Business Wire)
Jan-17-24 04:03PM	Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle (Investor's Business Daily) +7.30%
Jan-16-24 05:17PM	Natera Provides Update on Ravgen Trial (Business Wire)
Jan-09-24 07:00AM	Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues (Business Wire)
Dec-30-23 11:01AM	Insider Sell: CFO Michael Brophy Sells 2,292 Shares of Natera Inc (NTRA) (GuruFocus.com)
Dec-29-23 08:00AM	Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-27-23 11:48PM	Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics RaDaR Test (Business Wire)
Dec-26-23 06:56PM	13 High Growth Healthcare Stocks to Buy (Insider Monkey)
Dec-21-23 08:00AM	Natera Announces New Study Highlighting the Benefits of Signateras Unique Method of Quantifying ctDNA (Business Wire) +5.25%
Dec-11-23 12:50PM	Delaware Court Denies CareDxs Motion for Summary Judgment on Two Natera Patents (Business Wire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-06-23 08:30AM	Natera Presents New Signatera MRD Data Across Breast Cancer Treatment Settings at SABCS 2023 (Business Wire)
Dec-02-23 07:06AM	Insider Sell Alert: Director Rowan Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Nov-23-23 11:03AM	Insider Sell: CEO Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Nov-14-23 08:00AM	Natera Announces Real-World Data Collaboration with Merck (Business Wire) +7.38%
Nov-13-23 11:24AM	Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:02PM	Natera: Q3 Earnings Snapshot (Associated Press Finance) -5.27%
04:05PM	Natera Reports Third Quarter 2023 Financial Results (Business Wire)
09:10AM	Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer (Business Wire)
Nov-07-23 08:30AM	Natera to Participate in November Investor Conferences (Business Wire)
Nov-02-23 08:30AM	Nateras Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease (Business Wire)
Oct-25-23 09:02AM	Insider Sell: CFO Michael Brophy Sells 3,940 Shares of Natera Inc (GuruFocus.com)
Oct-22-23 01:00PM	Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signateras Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients (Business Wire)
Oct-20-23 09:00AM	Natera to Report its Third Quarter 2023 Results on November 8 (Business Wire)
Oct-19-23 09:00AM	Natera Recognized on U.S. News & World Reports 2024 Best Companies to Work for in Healthcare Ranking (Business Wire)
Oct-17-23 09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (PR Newswire)
Oct-16-23 09:00AM	Natera to Present New Signatera MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study (Business Wire)
Oct-04-23 09:00AM	New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signateras Ability to Risk Stratify and Detect Progression Early (Business Wire)
Oct-03-23 04:43PM	Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera (Business Wire)
Oct-02-23 09:00AM	Natera Submits First PMA Module to the FDA for Signatera (Business Wire)
Sep-30-23 05:01AM	Insider Sell: CFO Michael Brophy Sells 2,291 Shares of Natera Inc (GuruFocus.com)
Sep-18-23 09:00AM	Natera Announces Senior Leadership Appointments (Business Wire)
Sep-14-23 07:37PM	Unveiling Natera (NTRA)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com) -5.21%
09:00AM	Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera for Breast Cancer Patients in the Neoadjuvant Setting (Business Wire)
Sep-07-23 12:09AM	Natera Announces Pricing of $250 Million Follow-On Offering (Business Wire)
Sep-06-23 04:24PM	Natera Launches Proposed Follow-On Offering (Business Wire)
Sep-05-23 10:09AM	Natera (NTRA) Reported Solid Quarterly Revenue Despite a Share Price Decline (Insider Monkey)
Sep-04-23 12:17PM	Why Natera Inc's Stock Skyrocketed 27% in a Quarter: A Deep Dive (GuruFocus.com)
Sep-01-23 09:00AM	Natera to Participate in Upcoming Investor Conferences (Business Wire) +6.45%
Aug-18-23 07:39AM	Stanley Druckenmiller 13F Portfolio: Top 15 Stocks (Insider Monkey)
Aug-16-23 09:00AM	Nateras Prospera Lung Transplant Assessment Test Granted Medicare Coverage (Business Wire)
Aug-11-23 01:37PM	Natera Stock Showing Rising Market Leadership, Earns 82 RS Rating (Investor's Business Daily) +5.38%
Aug-05-23 06:27AM	Natera, Inc. (NASDAQ:NTRA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-04-23 11:15AM	Why Natera Stock Is Soaring Today (Motley Fool) +17.56%
06:58AM	Q2 2023 Natera Inc Earnings Call (Thomson Reuters StreetEvents)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	May 01 '24	Sale	93.97	1,866	175,344	67,542	May 03 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 29 '24	Sale	93.14	4,084	380,378	226,235	May 01 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 29 '24	Sale	93.14	1,238	115,306	69,408	May 01 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 29 '24	Sale	93.14	1,196	111,394	115,833	May 01 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 29 '24	Sale	93.14	1,057	98,448	204,495	May 01 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Apr 29 '24	Sale	93.14	929	86,526	110,748	May 01 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 26 '24	Sale	92.00	751	69,092	70,646	Apr 26 09:35 PM
Sheena Jonathan	CO-FOUNDER	Apr 25 '24	Sale	89.55	1,000	89,550	69,082	Apr 26 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 25 '24	Sale	89.55	705	63,133	71,397	Apr 26 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 24 '24	Sale	93.00	937	87,140	72,102	Apr 26 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 23 '24	Sale	91.38	2,552	233,200	230,319	Apr 23 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 23 '24	Sale	91.38	1,523	139,171	73,039	Apr 23 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Apr 23 '24	Sale	91.38	787	71,915	205,552	Apr 23 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 23 '24	Sale	91.38	531	48,522	117,029	Apr 23 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Apr 23 '24	Sale	91.38	522	47,700	111,677	Apr 23 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Apr 16 '24	Sale	90.82	80,000	7,265,651	117,560	Apr 17 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Apr 15 '24	Sale	93.13	6,816	634,797	227,710	Apr 17 09:05 PM
Sheena Jonathan	CO-FOUNDER	Apr 03 '24	Sale	92.47	26,700	2,468,822	321,031	Apr 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Apr 02 '24	Sale	92.62	1,378	127,629	70,646	Apr 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 28 '24	Sale	90.42	2,662	240,687	234,526	Mar 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 28 '24	Sale	90.13	1,000	90,130	69,582	Mar 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 28 '24	Sale	90.42	914	82,640	72,024	Mar 29 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 28 '24	Sale	90.42	743	67,179	204,839	Mar 29 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 28 '24	Sale	90.42	707	63,924	197,560	Mar 29 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Mar 28 '24	Sale	90.42	464	41,953	112,199	Mar 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 28 '24	Sale	90.22	447	40,326	347,731	Mar 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 15 '24	Option Exercise	19.37	68,270	1,322,406	315,227	Mar 15 09:05 PM
BOTHA ROELOF	Director	Mar 15 '24	Option Exercise	42.17	19,924	840,197	20,276	Mar 15 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 15 '24	Sale	88.96	83,223	7,403,534	232,004	Mar 15 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 15 '24	Sale	89.02	50,910	4,532,065	0	Mar 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Mar 06 '24	Sale	88.70	5,000	443,492	458,585	Mar 07 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 05 '24	Sale	87.40	190,000	16,605,069	860,036	Mar 07 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 05 '24	Sale	88.36	9,326	824,092	246,957	Mar 07 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Mar 05 '24	Sale	88.36	2,826	249,719	70,646	Mar 07 09:40 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 05 '24	Sale	88.36	2,245	198,361	198,267	Mar 07 09:40 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Mar 05 '24	Sale	88.36	2,160	190,868	204,218	Mar 07 09:40 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Mar 05 '24	Sale	88.36	1,838	162,400	112,663	Mar 07 09:40 PM
Sheena Jonathan	CO-FOUNDER	Mar 05 '24	Sale	88.36	1,028	90,839	463,585	Mar 07 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 05 '24	Sale	88.36	1,012	89,416	1,075,648	Mar 07 09:40 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 29 '24	Option Exercise	9.29	20,526	190,687	224,744	Feb 29 09:15 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 29 '24	Sale	89.01	20,526	1,826,970	204,218	Feb 29 09:15 PM
Sheena Jonathan	CO-FOUNDER	Feb 29 '24	Sale	86.34	10,000	863,433	463,585	Mar 01 08:45 PM
Sheena Jonathan	CO-FOUNDER	Feb 29 '24	Sale	90.02	6,000	540,109	14,655	Mar 01 08:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 27 '24	Option Exercise	10.16	35,307	358,802	239,525	Feb 29 09:15 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 27 '24	Sale	75.09	35,307	2,651,298	204,218	Feb 29 09:15 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Feb 23 '24	Option Exercise	2.66	380,036	1,009,718	1,050,036	Feb 23 09:40 PM
ROSENMAN HERM	Director	Feb 16 '24	Option Exercise	2.66	93,901	249,486	155,586	Feb 16 09:45 PM
ROSENMAN HERM	Director	Feb 16 '24	Sale	69.37	93,901	6,514,371	61,685	Feb 16 09:45 PM
Sheena Jonathan	CO-FOUNDER	Feb 07 '24	Sale	70.10	5,000	350,486	473,585	Feb 08 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 07 '24	Sale	70.10	1,000	70,099	17,655	Feb 08 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 06 '24	Option Exercise	16.61	34,029	565,063	104,675	Feb 08 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 06 '24	Sale	70.03	34,029	2,383,129	70,646	Feb 08 09:40 PM
Sheena Jonathan	CO-FOUNDER	Feb 06 '24	Sale	70.00	6,000	420,011	18,155	Feb 08 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	67.73	22,281	1,509,081	70,646	Feb 02 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 29 '24	Sale	65.09	14,813	964,194	246,957	Jan 30 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 29 '24	Sale	65.09	4,265	277,614	204,218	Jan 30 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 29 '24	Sale	65.09	3,426	223,002	194,977	Jan 30 09:02 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '24	Sale	65.09	3,235	210,570	92,927	Jan 30 09:15 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 29 '24	Sale	65.09	2,358	153,485	108,494	Jan 30 08:57 PM
Sheena Jonathan	CO-FOUNDER	Jan 29 '24	Sale	65.09	546	35,540	478,585	Jan 30 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 24 '24	Sale	67.00	944	63,248	64,810	Jan 26 09:40 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 23 '24	Sale	65.86	2,202	145,014	65,754	Jan 23 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 22 '24	Sale	68.16	1,958	133,457	175,550	Jan 23 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 22 '24	Sale	68.16	892	60,799	181,050	Jan 23 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 22 '24	Sale	68.16	771	52,551	67,956	Jan 23 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jan 22 '24	Sale	68.16	351	23,924	469,726	Jan 23 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 03 '24	Sale	60.30	5,000	301,499	469,743	Jan 05 08:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 03 '24	Sale	60.45	1,000	60,451	21,155	Jan 05 08:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Dec 29 '23	Sale	62.29	1,377	85,773	64,810	Dec 29 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 28 '23	Sale	63.29	2,604	164,813	172,348	Dec 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Dec 28 '23	Sale	62.12	1,000	62,120	21,655	Dec 29 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Dec 28 '23	Sale	63.29	915	57,912	66,187	Dec 29 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 28 '23	Sale	63.29	728	46,077	180,442	Dec 29 09:05 PM
Sheena Jonathan	CO-FOUNDER	Dec 28 '23	Sale	62.44	447	27,909	474,743	Dec 29 09:05 PM
HEALY JAMES	Director	Dec 13 '23	Sale	58.75	644,000	37,835,000	0	Dec 22 02:21 PM
Marcus Gail Boxer	Director	Dec 08 '23	Sale	57.52	500	28,760	20,146	Dec 12 08:35 PM
Sheena Jonathan	CO-FOUNDER	Dec 06 '23	Sale	58.22	5,000	291,078	474,743	Dec 08 08:35 PM
Chapman Rowan E	Director	Nov 29 '23	Sale	55.97	1,998	111,831	9,373	Dec 01 08:35 PM
Marcus Gail Boxer	Director	Nov 21 '23	Sale	54.31	1,000	54,314	20,646	Nov 22 08:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 20 '23	Sale	55.00	2,566	141,130	217,554	Nov 22 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 02 '23	Sale	40.23	5,000	201,150	479,743	Nov 03 09:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 02 '23	Sale	40.35	1,000	40,351	22,155	Nov 03 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 23 '23	Sale	40.40	3,940	159,195	64,810	Oct 24 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 23 '23	Sale	40.39	2,595	104,813	220,120	Oct 24 09:35 PM
Sheena Jonathan	CO-FOUNDER	Oct 23 '23	Sale	40.04	1,000	40,037	22,655	Oct 24 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 23 '23	Sale	40.39	803	32,433	179,807	Oct 24 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 23 '23	Sale	40.19	335	13,464	484,743	Oct 24 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Sep 29 '23	Sale	45.98	1,372	63,080	64,833	Sep 29 09:45 PM
Sheena Jonathan	CO-FOUNDER	Sep 28 '23	Sale	46.06	5,448	250,909	484,745	Sep 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Sep 28 '23	Sale	45.82	2,617	119,901	217,554	Sep 29 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Sep 28 '23	Sale	45.82	919	42,105	66,205	Sep 29 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Sep 28 '23	Sale	45.82	732	33,537	179,110	Sep 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Sep 06 '23	Sale	59.07	5,000	295,365	489,746	Sep 08 09:05 PM
Sheena Jonathan	CO-FOUNDER	Sep 06 '23	Sale	59.23	1,000	59,227	23,155	Sep 08 09:05 PM
Sheena Jonathan	CO-FOUNDER	Sep 01 '23	Sale	60.01	10,000	600,062	494,746	Sep 01 09:30 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Aug 11 '23	Sale	55.00	2,578	141,790	214,988	Aug 14 09:05 PM
Sheena Jonathan	CO-FOUNDER	Aug 02 '23	Sale	44.22	5,000	221,116	504,746	Aug 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Aug 02 '23	Sale	44.15	1,000	44,149	23,655	Aug 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jul 25 '23	Sale	46.58	2,347	109,323	64,833	Jul 27 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jul 24 '23	Sale	47.83	2,578	123,296	217,566	Jul 24 09:45 PM

Open in Screener

EXAS

Exact Sciences Corp.

May 03 • 04:00PM ET

62.07

Dollar change +1.53
Percentage change 2.53	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

EXAS Exact Sciences Corp. daily Stock Chart

Held by: VTI VB VXF VBK ARKK ARKG VHT IWR FBT SCHM

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	1.04%	Shs Outstand	183.85M	Perf Week	5.47%
Market Cap	11.41B	Forward P/E	472.73	EPS next Y	0.13	Insider Trans	-5.37%	Shs Float	181.94M	Perf Month	-11.53%
Income	-204.15M	PEG	-	EPS next Q	-0.48	Inst Own	84.61%	Short Float	5.44%	Perf Quarter	-3.09%
Sales	2.50B	P/S	4.57	EPS this Y	20.56%	Inst Trans	-1.72%	Short Ratio	3.99	Perf Half Y	-2.28%
Book/sh	17.34	P/B	3.58	EPS next Y	114.63%	ROA	-3.00%	Short Interest	9.89M	Perf Year	-2.54%
Cash/sh	4.23	P/C	14.67	EPS next 5Y	-	ROE	-6.60%	52W Range	56.05 - 100.77	Perf YTD	-16.10%
Dividend Est.	-	P/FCF	357.39	EPS past 5Y	4.59%	ROI	-3.63%	52W High	-38.40%	Beta	1.32
Dividend TTM	-	Quick Ratio	2.07	Sales past 5Y	43.88%	Gross Margin	70.14%	52W Low	10.74%	ATR (14)	2.92
Dividend Ex-Date	-	Current Ratio	2.32	EPS Y/Y TTM	67.92%	Oper. Margin	-12.20%	RSI (14)	46.55	Volatility	3.96% 4.31%
Employees	6600	Debt/Eq	0.82	Sales Y/Y TTM	19.93%	Profit Margin	-8.17%	Recom	1.33	Target Price	90.66
Option/Short	Yes / Yes	LT Debt/Eq	0.79	EPS Q/Q	61.80%	Payout	-	Rel Volume	0.65	Prev Close	60.54
Sales Surprise	1.26%	EPS Surprise	36.16%	Sales Q/Q	16.98%	Earnings	May 08 AMC	Avg Volume	2.48M	Price	62.07
SMA20	-4.22%	SMA50	-1.62%	SMA200	-10.49%	Trades		Volume	1,612,443	Change	2.53%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy	$91
Dec-14-23	Initiated	Guggenheim	Buy	$90
Dec-13-23	Initiated	Wolfe Research	Outperform	$95
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$90
Sep-28-23	Initiated	Bernstein	Outperform	$83
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy	$55 → $85
May-05-23	Initiated	UBS	Neutral	$73
Mar-09-23	Upgrade	Citigroup	Neutral → Buy	$70 → $90
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$50 → $70
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold	$60 → $35
Aug-25-22	Initiated	Credit Suisse	Outperform	$55
Jun-03-22	Initiated	Piper Sandler	Neutral	$50
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform	$160 → $130
Jul-29-21	Reiterated	Stifel	Buy	$165 → $145
Jul-29-21	Reiterated	Oppenheimer	Outperform	$161 → $155
Jul-29-21	Reiterated	Canaccord Genuity	Buy	$185 → $160
Jul-29-21	Reiterated	BTIG Research	Buy	$155 → $145
Jun-15-21	Initiated	Raymond James	Strong Buy	$160

Show Previous Ratings

May-01-24 06:00AM	Exact Sciences to Participate in May Investor Conference (Business Wire)
Apr-25-24 08:05PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) -7.04%
Apr-24-24 06:15PM	Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
07:16AM	Here's Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS) (Insider Monkey)
Apr-22-24 12:44PM	Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings? (Zacks)
11:10AM	Loading…
11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-17-24 06:15PM	Why Exact Sciences (EXAS) Dipped More Than Broader Market Today (Zacks)
Apr-15-24 06:52AM	Exact Sciences names Aaron Bloomer CFO (MedTech Dive) -8.40%
06:00AM	Exact Sciences Names Aaron Bloomer as New Chief Financial Officer (Business Wire)
Apr-12-24 07:00AM	Here's Why Exact Sciences Corporation (EXAS) Declined in Q1 (Insider Monkey)
06:49AM	Should You Hold ON Semiconductor Corporation (ON)? (Insider Monkey)
06:40AM	Should You be Bullish on the Long-Term Growth of Atlassian Corporation (TEAM)? (Insider Monkey)
Apr-11-24 06:00AM	Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes (Business Wire)
Apr-10-24 06:15PM	Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know (Zacks)
08:16AM	Search for Cancer Blood Test Continues Despite Illumina-Grail Deals Failure (Barrons.com)
12:00AM	Loading…
12:00AM	ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? (TipRanks)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 12:05PM	Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 (Business Wire)
07:00AM	Sorry, but Blood Tests Wont Replace Stool Samples or Colonoscopies Yet (The Wall Street Journal)
06:00AM	Exact Sciences Schedules First Quarter 2024 Earnings Call (Business Wire)
Apr-05-24 10:16AM	Freenomes colorectal cancer blood test data underwhelm analysts (MedTech Dive)
Apr-04-24 10:15AM	1 Beaten-Down Cathie Wood Stock to Buy and Hold (Motley Fool)
06:05AM	Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment (Business Wire)
Apr-03-24 09:57AM	Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising (Zacks)
Apr-02-24 04:02PM	Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales (Investor's Business Daily)
Mar-29-24 08:09AM	Exact Sciences, Mayo Clinic share early data on esophageal cancer test (MedTech Dive)
Mar-28-24 06:00AM	Exact Sciences Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer (Business Wire)
Mar-27-24 08:05AM	Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner (Business Wire)
Mar-26-24 07:00AM	3 Growth Stocks to Buy at 52-Week Lows in March (InvestorPlace)
Mar-25-24 09:55AM	How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83% (Zacks)
11:30AM	Loading…
Mar-22-24 11:30AM	Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-18-24 08:19AM	Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM (Zacks)
04:30AM	Guardant posts data for colon cancer blood test amid push from rivals (MedTech Dive)
Mar-14-24 04:16PM	Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates (Investor's Business Daily)
Mar-13-24 05:03PM	The New England Journal of Medicine Publishes Cologuard Plus Test Results from Pivotal BLUE-C Study (Business Wire)
Mar-11-24 12:59AM	2 Beaten-Down Cathie Wood Stocks With Massive Potential (Motley Fool)
Mar-08-24 09:55AM	Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-07-24 07:59AM	Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer (Business Wire) +9.22%
Mar-04-24 11:52PM	Exact Sciences Corp (EXAS) Director Daniel Levangie Sells 5,000 Shares (GuruFocus.com)
03:49PM	The Top 3 Healthcare Stocks to Buy on Weakness in 2024 (InvestorPlace)
10:38AM	7 Stable Stocks to Buy for 100% Returns by 2025 (InvestorPlace)
Mar-03-24 10:32AM	Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices (InvestorPlace)
Feb-26-24 06:00AM	Exact Sciences to Participate in March Investor Conference (Business Wire)
Feb-23-24 12:01PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
Feb-22-24 11:08AM	Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.00%
10:30AM	Q4 2023 Exact Sciences Corp Earnings Call (Thomson Reuters StreetEvents)
10:22AM	Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y (Zacks)
01:30AM	Exact Sciences (EXAS) Q4 2023 Earnings Call Transcript (Motley Fool)
12:06AM	Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight (GuruFocus.com)
Feb-21-24 06:20PM	Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Exact Sciences: Q4 Earnings Snapshot (Associated Press Finance)
05:12PM	Exact Sciences Corp Reports Robust Revenue Growth and Positive Free Cash Flow in Q4 2023 (GuruFocus.com)
04:05PM	Exact Sciences Announces Fourth Quarter 2023 Results (Business Wire)
Feb-20-24 02:39AM	LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy? (TipRanks)
Feb-15-24 07:47AM	Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store? (Zacks)
Feb-14-24 10:00AM	Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-13-24 08:12PM	Analyst Report: Exact Sciences Corporation (Morningstar Research)
Feb-10-24 05:06PM	Top 5 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 09:00AM	Cathie Wood Is Selling This Stock: Should You? (Motley Fool) -5.36%
Feb-01-24 06:00AM	Exact Sciences Schedules Fourth Quarter 2023 Earnings Call (Business Wire)
Jan-28-24 09:25AM	3 Stocks to Buy for the Age of Personalized Medicine (InvestorPlace)
Jan-22-24 08:00AM	2 Cathie Wood Growth Stocks to Buy and Hold for the Long Haul (Motley Fool)
Jan-18-24 05:04AM	The Top 3 Stocks in the High-Potential Cancer Testing Market (InvestorPlace)
Jan-13-24 02:05PM	BIIB, ZTS, EXAS: Which Strong Buy Healthcare Stock is Best? (TipRanks)
Jan-08-24 02:48PM	7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 (InvestorPlace)
Jan-07-24 04:30PM	Exact Sciences Announces Preliminary Fourth Quarter 2023 Results (PR Newswire)
Jan-02-24 06:00AM	Exact Sciences to participate in J.P. Morgan Healthcare Conference (PR Newswire)
Dec-21-23 09:43AM	Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid (Zacks) +6.14%
Dec-20-23 01:49PM	5 Most Promising Gene Editing Stocks According to Hedge Funds (Insider Monkey)
Dec-17-23 05:43AM	1 Supercharged Growth Stock to Buy Before It Soars as Much as 222%, According to Cathie Wood's Ark Invest (Motley Fool)
Dec-14-23 04:02AM	Ark Invest Stock Portfolio: 16 Biggest Positions (Insider Monkey)
Dec-13-23 12:52PM	Here's Why You Should Retain Exact Sciences (EXAS) Stock Now (Zacks)
08:45AM	Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? (Motley Fool)
Dec-07-23 08:05AM	Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings (PR Newswire)
Dec-05-23 09:11AM	3 Stocks at the Forefront of Personalized Medicine Trend (InvestorPlace)
Dec-04-23 12:13PM	Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue? (Zacks)
Dec-01-23 11:32AM	Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report? (Zacks)
05:26AM	Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3 (Insider Monkey)
Nov-30-23 04:05PM	Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients (PR Newswire)
Nov-25-23 09:45AM	The 3 Best Digital Health Stocks for Personalized Medicine (InvestorPlace)
Nov-23-23 12:02PM	15 Stocks with Consistent Growth (Insider Monkey)
Nov-20-23 03:06PM	3 Biotech Stocks With Big-Time Breakthrough Potential (InvestorPlace)
09:55AM	Wall Street Analysts See a 51.73% Upside in Exact Sciences (EXAS): Can the Stock Really Move This High? (Zacks)
07:30AM	2 Revolutionary Stocks That Could Turn $1,000 Into $2,000 by 2030 (Motley Fool)
Nov-17-23 08:04PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) +8.39%
07:10AM	Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy (PR Newswire)
Nov-14-23 05:20AM	3 Stocks to Love Despite All of the Wall Street Hate (InvestorPlace) +7.07%
Nov-10-23 07:00AM	7 Biotech Stocks to Buy for Big-Time Gains (InvestorPlace)
Nov-09-23 08:10PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) -5.09%
Nov-06-23 09:35AM	Exact Sciences (EXAS) Just Overtook the 20-Day Moving Average (Zacks)
Nov-03-23 08:09PM	Analyst Report: Exact Sciences Corporation (Morningstar Research) +7.30%
Nov-02-23 07:23PM	Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript (Insider Monkey)
04:02PM	Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth (Investor's Business Daily)
11:03AM	Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises (Zacks)
09:40AM	Q3 2023 Exact Sciences Corp Earnings Call (Thomson Reuters StreetEvents)
01:14AM	The Exact Sciences Corp (EXAS) Company: A Short SWOT Analysis (GuruFocus.com)
12:30AM	Exact Sciences (EXAS) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-01-23 06:06PM	Exact Sciences Corp (EXAS) Reports 20% Revenue Increase in Q3 2023 (GuruFocus.com)
04:05PM	Exact Sciences Announces Third-Quarter 2023 Results (PR Newswire)
06:00AM	Exact Sciences to participate in November investor conferences (PR Newswire)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Conroy Kevin T	President and CEO	May 01 '24	Sale	60.15	1,155	69,473	1,156,191	May 02 07:00 PM
Cunningham Everett	Chief Commercial Officer	May 01 '24	Sale	60.15	136	8,180	47,042	May 02 07:00 PM
Elliott Jeffrey Thomas	Chief Financial Officer	May 01 '24	Sale	60.15	136	8,180	11,795	May 02 07:00 PM
Baranick Brian	EVP, GM., Precision Oncology	May 01 '24	Sale	60.15	110	6,616	13,279	May 02 07:00 PM
ORVILLE JACOB A	General Manager, Screening	May 01 '24	Sale	60.15	102	6,135	14,440	May 02 07:00 PM
Condella Sarah	EVP, Human Resources	May 01 '24	Sale	60.15	102	6,135	72,611	May 02 07:00 PM
COWARD D SCOTT	Director	May 01 '24	Sale	60.15	67	4,030	44,644	May 02 07:00 PM
Herriott James	SVP, General Counsel & Sec	May 01 '24	Sale	60.15	30	1,804	9,866	May 02 07:00 PM
Baranick Brian	EVP, GM., Precision Oncology	Apr 02 '24	Sale	79.43	924	73,393	13,171	Apr 03 07:30 PM
Condella Sarah	EVP, Human Resources	Apr 01 '24	Sale	70.00	2,000	140,000	71,787	Apr 03 07:30 PM
Condella Sarah	EVP, Human Resources	Mar 28 '24	Sale	70.00	2,000	140,000	73,787	Apr 01 04:30 PM
Conroy Kevin T	President and CEO	Mar 01 '24	Sale	59.32	8,271	490,636	1,299,496	Mar 04 08:38 PM
LEVANGIE DANIEL J	Director	Mar 01 '24	Sale	57.50	5,000	287,500	22,975	Mar 04 08:42 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	10,933	Mar 04 08:40 PM
Cunningham Everett	Chief Commercial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	46,179	Mar 04 08:38 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Mar 01 '24	Sale	59.32	2,323	137,800	14,095	Mar 04 08:36 PM
ORVILLE JACOB A	General Manager, Screening	Mar 01 '24	Sale	59.32	2,154	127,775	14,324	Mar 04 08:42 PM
Doyle James Edward	Director	Mar 01 '24	Sale	57.50	2,000	115,000	50,110	Mar 04 08:39 PM
Condella Sarah	EVP, Human Resources	Mar 01 '24	Sale	59.32	1,724	102,268	75,787	Mar 04 08:37 PM
Herriott James	General Counsel	Mar 01 '24	Sale	59.32	862	51,134	9,125	Mar 04 08:41 PM
Herriott James	General Counsel	Feb 29 '24	Option Exercise	0.00	1,890	0	9,987	Mar 04 08:41 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	13,345	Mar 04 08:40 PM
Cunningham Everett	Chief Commercial Officer	Feb 29 '24	Option Exercise	0.00	5,291	0	48,591	Mar 04 08:38 PM
ORVILLE JACOB A	General Manager, Screening	Feb 29 '24	Option Exercise	0.00	4,724	0	16,478	Mar 04 08:42 PM
Conroy Kevin T	President and CEO	Feb 29 '24	Option Exercise	0.00	18,143	0	1,307,767	Mar 04 08:38 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 29 '24	Option Exercise	0.00	4,724	0	16,418	Mar 04 08:36 PM
Condella Sarah	EVP, Human Resources	Feb 29 '24	Option Exercise	0.00	3,779	0	77,511	Mar 04 08:37 PM
Conroy Kevin T	President and CEO	Feb 27 '24	Sale	56.89	6,263	356,302	1,289,624	Feb 28 07:35 PM
Cunningham Everett	Chief Commercial Officer	Feb 27 '24	Sale	56.89	3,648	207,535	43,300	Feb 28 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 27 '24	Sale	56.89	2,710	154,172	8,054	Feb 28 07:36 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 27 '24	Sale	56.89	2,027	115,316	11,694	Feb 28 07:34 PM
Condella Sarah	EVP, Human Resources	Feb 27 '24	Sale	56.89	1,880	106,953	73,732	Feb 28 07:35 PM
ORVILLE JACOB A	General Manager, Screening	Feb 27 '24	Sale	56.89	1,879	106,896	11,754	Feb 28 07:38 PM
Herriott James	General Counsel	Feb 27 '24	Sale	56.89	784	44,602	8,097	Feb 28 07:38 PM
Cunningham Everett	Chief Commercial Officer	Feb 26 '24	Option Exercise	0.00	7,678	0	46,948	Feb 28 07:37 PM
ORVILLE JACOB A	General Manager, Screening	Feb 26 '24	Option Exercise	0.00	3,954	0	13,633	Feb 28 07:38 PM
Herriott James	General Counsel	Feb 26 '24	Option Exercise	0.00	1,648	0	8,881	Feb 28 07:38 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 26 '24	Option Exercise	0.00	5,701	0	10,764	Feb 28 07:36 PM
Condella Sarah	EVP, Human Resources	Feb 26 '24	Option Exercise	0.00	3,954	0	75,612	Feb 28 07:35 PM
Conroy Kevin T	President and CEO	Feb 26 '24	Option Exercise	0.00	13,181	0	1,295,887	Feb 28 07:35 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 26 '24	Option Exercise	0.00	3,954	0	13,721	Feb 28 07:34 PM
Conroy Kevin T	President and CEO	Feb 23 '24	Option Exercise	13.96	102,837	1,435,605	1,344,266	Feb 26 05:00 PM
Condella Sarah	EVP, Human Resources	Feb 23 '24	Sale	59.72	1,021	60,974	71,658	Feb 26 05:00 PM
Conroy Kevin T	President and CEO	Feb 22 '24	Sale	59.78	11,565	691,356	1,241,429	Feb 23 07:59 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 22 '24	Sale	59.78	1,351	80,763	5,063	Feb 23 08:01 PM
Cunningham Everett	Chief Commercial Officer	Feb 22 '24	Sale	59.78	1,350	80,703	39,270	Feb 23 08:00 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 22 '24	Sale	59.78	1,093	65,340	9,767	Feb 23 07:57 PM
Condella Sarah	EVP, Human Resources	Feb 22 '24	Sale	59.78	1,013	60,557	72,679	Feb 23 07:57 PM
ORVILLE JACOB A	General Manager, Screening	Feb 22 '24	Sale	59.78	1,013	60,557	9,679	Feb 23 08:03 PM
COWARD D SCOTT	Director	Feb 22 '24	Sale	59.78	663	39,634	44,493	Feb 23 07:59 PM
Herriott James	General Counsel	Feb 22 '24	Sale	59.78	291	17,396	7,233	Feb 23 08:02 PM
Conroy Kevin T	President and CEO	Feb 21 '24	Sale	61.50	4,975	305,962	1,229,756	Feb 22 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 21 '24	Sale	61.50	1,493	91,820	3,703	Feb 22 07:38 PM
Condella Sarah	EVP, Human Resources	Feb 21 '24	Sale	61.50	1,079	66,358	71,658	Feb 22 07:36 PM
ORVILLE JACOB A	General Manager, Screening	Feb 21 '24	Sale	61.50	1,078	66,297	8,658	Feb 22 07:40 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 21 '24	Sale	61.50	895	55,042	8,826	Feb 22 07:36 PM
COWARD D SCOTT	Director	Feb 21 '24	Sale	61.50	706	43,419	43,122	Feb 22 07:38 PM
Herriott James	General Counsel	Feb 21 '24	Sale	61.50	415	25,522	6,943	Feb 22 07:39 PM
Conroy Kevin T	President and CEO	Feb 20 '24	Option Exercise	0.00	10,374	0	1,234,731	Feb 22 07:37 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 20 '24	Option Exercise	0.00	3,112	0	5,196	Feb 22 07:38 PM
COWARD D SCOTT	Director	Feb 20 '24	Option Exercise	0.00	2,248	0	43,828	Feb 22 07:38 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Feb 20 '24	Option Exercise	0.00	1,729	0	9,721	Feb 22 07:36 PM
Condella Sarah	EVP, Human Resources	Feb 20 '24	Option Exercise	0.00	2,248	0	72,737	Feb 22 07:36 PM
Herriott James	General Counsel	Feb 20 '24	Option Exercise	0.00	864	0	7,358	Feb 22 07:39 PM
ORVILLE JACOB A	General Manager, Screening	Feb 20 '24	Option Exercise	0.00	2,248	0	9,736	Feb 22 07:40 PM
Conroy Kevin T	President and CEO	Feb 15 '24	Sale	61.43	14,791	908,611	1,224,357	Feb 16 06:22 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 15 '24	Sale	61.43	1,888	115,980	2,084	Feb 16 06:24 PM
COWARD D SCOTT	Director	Feb 15 '24	Sale	61.43	1,376	84,528	41,580	Feb 16 06:23 PM
ORVILLE JACOB A	General Manager, Screening	Feb 15 '24	Sale	61.43	966	59,341	7,488	Feb 16 06:26 PM
Condella Sarah	EVP, Human Resources	Feb 15 '24	Sale	61.43	965	59,280	70,489	Feb 16 06:21 PM
Herriott James	General Counsel	Feb 15 '24	Sale	61.43	421	25,862	6,494	Feb 16 06:25 PM
Herriott James	General Counsel	Feb 14 '24	Option Exercise	0.00	883	0	6,915	Feb 16 06:25 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Feb 14 '24	Option Exercise	0.00	3,972	0	3,972	Feb 16 06:24 PM
COWARD D SCOTT	Director	Feb 14 '24	Option Exercise	0.00	3,972	0	42,956	Feb 16 06:23 PM
Condella Sarah	EVP, Human Resources	Feb 14 '24	Option Exercise	0.00	2,031	0	71,454	Feb 16 06:21 PM
ORVILLE JACOB A	General Manager, Screening	Feb 14 '24	Option Exercise	0.00	2,031	0	8,454	Feb 16 06:26 PM
Conroy Kevin T	President and CEO	Feb 14 '24	Option Exercise	0.00	31,133	0	1,239,148	Feb 16 06:22 PM
Condella Sarah	EVP, Human Resources	Jan 02 '24	Sale	73.50	2,000	147,000	69,423	Jan 04 05:19 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Jan 02 '24	Sale	73.50	879	64,606	7,992	Jan 04 05:17 PM
Condella Sarah	EVP, Human Resources	Dec 14 '23	Sale	70.00	2,000	140,000	71,423	Dec 18 07:49 PM
Cunningham Everett	Chief Commercial Officer	Oct 12 '23	Sale	66.49	13,007	864,835	37,909	Oct 13 07:59 PM
Cunningham Everett	Chief Commercial Officer	Oct 11 '23	Option Exercise	0.00	27,504	0	50,916	Oct 13 07:59 PM
Condella Sarah	EVP, Human Resources	Sep 01 '23	Sale	84.36	4,500	379,620	75,814	Sep 06 04:04 PM
Elliott Jeffrey Thomas	Chief Financial Officer	Aug 21 '23	Sale	82.92	30,210	2,505,013	0	Aug 23 04:08 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Aug 07 '23	Sale	85.04	1,350	114,804	8,871	Aug 08 04:09 PM
Baranick Brian	Gen. Mgr., Precision Oncology	Aug 04 '23	Option Exercise	0.00	2,712	0	10,221	Aug 08 04:09 PM
Doyle James Edward	Director	Jul 27 '23	Sale	97.42	2,000	194,840	52,110	Jul 28 04:06 PM
Herriott James	General Counsel	Jul 19 '23	Sale	100.00	1,300	130,000	5,964	Jul 21 04:04 PM
Zanotti Katherine S	Director	Jun 09 '23	Sale	90.51	3,027	273,974	64,629	Jun 12 04:17 PM
Doyle James Edward	Director	Jun 09 '23	Sale	90.51	1,402	126,895	54,110	Jun 12 04:29 PM
Herriott James	General Counsel	Jun 08 '23	Sale	90.00	1,300	117,000	7,264	Jun 12 04:14 PM
Doyle James Edward	Director	May 26 '23	Sale	80.62	2,000	161,240	51,913	May 31 04:13 PM
Condella Sarah	EVP, Human Resources	May 10 '23	Sale	80.00	6,087	486,960	80,314	May 12 04:11 PM
ORVILLE JACOB A	General Manager, Screening	May 10 '23	Sale	80.00	5,000	400,000	6,423	May 12 04:09 PM
Herriott James	General Counsel	May 10 '23	Sale	79.85	1,300	103,805	8,564	May 12 04:07 PM

Open in Screener

LH

Laboratory Corp. Of America Holdings

May 03 • 04:00PM ET

201.32

Dollar change +1.07
Percentage change 0.53	%

Healthcare • Diagnostics & Research • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

LH Laboratory Corp. Of America Holdings daily Stock Chart

Held by: VTI VOO VO IVV VTV VOE RSP VHT SPLV IWR

Index	S&P 500	P/E	40.65	EPS (ttm)	4.95	Insider Own	0.39%	Shs Outstand	84.29M	Perf Week	1.47%
Market Cap	16.97B	Forward P/E	12.61	EPS next Y	15.97	Insider Trans	-15.18%	Shs Float	83.96M	Perf Month	-4.68%
Income	433.10M	PEG	4.74	EPS next Q	3.81	Inst Own	98.43%	Short Float	2.70%	Perf Quarter	-9.13%
Sales	12.30B	P/S	1.38	EPS this Y	9.40%	Inst Trans	-2.80%	Short Ratio	2.84	Perf Half Y	-1.29%
Book/sh	94.42	P/B	2.13	EPS next Y	7.63%	ROA	2.17%	Short Interest	2.26M	Perf Year	3.70%
Cash/sh	1.18	P/C	170.89	EPS next 5Y	8.58%	ROE	4.36%	52W Range	179.58 - 234.09	Perf YTD	-11.43%
Dividend Est.	2.52 (1.25%)	P/FCF	24.84	EPS past 5Y	-11.14%	ROI	3.70%	52W High	-14.00%	Beta	1.06
Dividend TTM	2.88 (1.43%)	Quick Ratio	0.76	Sales past 5Y	2.87%	Gross Margin	25.90%	52W Low	12.11%	ATR (14)	4.24
Dividend Ex-Date	May 28, 2024	Current Ratio	0.88	EPS Y/Y TTM	-54.91%	Oper. Margin	9.05%	RSI (14)	42.37	Volatility	2.36% 1.91%
Employees	67000	Debt/Eq	0.75	Sales Y/Y TTM	-16.64%	Profit Margin	3.52%	Recom	1.75	Target Price	241.38
Option/Short	Yes / Yes	LT Debt/Eq	0.47	EPS Q/Q	12.53%	Payout	60.36%	Rel Volume	0.70	Prev Close	200.25
Sales Surprise	1.88%	EPS Surprise	5.61%	Sales Q/Q	-15.92%	Earnings	Apr 25 BMO	Avg Volume	796.27K	Price	201.32
SMA20	-1.31%	SMA50	-4.35%	SMA200	-5.42%	Trades		Volume	555,653	Change	0.53%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-24	Upgrade	Argus	Hold → Buy	$250
Feb-26-24	Initiated	Leerink Partners	Outperform	$260
Feb-09-24	Initiated	Evercore ISI	In-line	$240
Jan-03-24	Initiated	Barclays	Equal Weight	$222
Sep-06-23	Initiated	HSBC Securities	Hold	$210
Dec-12-22	Downgrade	Citigroup	Buy → Neutral	$275 → $250
Sep-19-22	Downgrade	Argus	Buy → Hold
Aug-22-22	Resumed	Morgan Stanley	Overweight	$300
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold	$330 → $294
Jan-11-21	Upgrade	Argus	Hold → Buy	$245
Jan-11-21	Downgrade	Wolfe Research	Peer Perform → Underperform
Jan-08-21	Downgrade	Wolfe Research	Outperform → Peer Perform
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy	$194 → $220
Jul-13-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jun-02-20	Resumed	Deutsche Bank	Buy	$210
May-15-20	Upgrade	Mizuho	Neutral → Buy	$158 → $186
Apr-29-20	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-27-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Apr-27-20	Upgrade	Citigroup	Neutral → Buy	$204 → $214
Jan-08-20	Initiated	Wells Fargo	Overweight	$210

Show Previous Ratings

May-02-24 02:22AM	Insider Sale at Laboratory Corp of America Holdings (LH) (GuruFocus.com)
May-01-24 01:03AM	Decoding Laboratory Corp of America Holdings (LH): A Strategic SWOT Insight (GuruFocus.com)
Apr-30-24 01:58PM	Laboratory Corporation of America Holdings (NYSE:LH) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:41AM	Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244 (MT Newswires)
Apr-29-24 10:17AM	Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy (MT Newswires)
07:00AM	Loading…
07:00AM	Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B (PR Newswire)
Apr-26-24 11:14AM	Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 (MT Newswires)
10:34AM	Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 (MT Newswires)
07:55AM	Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating (MT Newswires)
01:06AM	Q1 2024 Laboratory Corporation of America Holdings Earnings Call (Thomson Reuters StreetEvents)
Apr-25-24 01:41PM	Analyst Report: Laboratory Corporation of America Holdings (Morningstar Research)
01:11PM	Labcorp to acquire Invitaes assets for $239M (MedTech Dive)
12:45PM	Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating (MT Newswires)
10:18AM	Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View (Zacks)
09:30AM	Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics (Zacks)
09:22AM	Loading…
09:22AM	Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated (MT Newswires)
08:35AM	Laboratory Corp of America Holdings (LH) Q1 Earnings: Surpasses Revenue Forecasts and Updates ... (GuruFocus.com)
07:09AM	Labcorp beats quarterly estimates on strong testing demand (Reuters)
07:06AM	Labcorp: Q1 Earnings Snapshot (Associated Press Finance)
06:58AM	Labcorp Announces 2024 First Quarter Results (PR Newswire)
Apr-24-24 10:25PM	Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 million (Reuters)
10:23PM	Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln (Reuters)
09:27PM	Labcorp Announces Winning Bid for Select Assets of Invitae (PR Newswire)
09:19PM	Invitae Enters into Agreement with Labcorp for Sale of Business (PR Newswire)
Apr-22-24 09:16AM	Exploring Analyst Estimates for Labcorp (LH) Q1 Earnings, Beyond Revenue and EPS (Zacks)
Apr-19-24 05:34AM	Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Revised) (Zacks)
Apr-18-24 12:10PM	Why Labcorp (LH) Could Beat Earnings Estimates Again (Zacks)
10:01AM	Labcorp (LH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-16-24 08:42AM	Labcorp (LH) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-15-24 07:00AM	Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw (PR Newswire)
09:10AM	Loading…
Apr-12-24 09:10AM	Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod (Zacks)
Apr-11-24 06:59AM	Labcorp Declares Quarterly Dividend (PR Newswire)
Apr-10-24 06:49AM	Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit (PR Newswire)
Apr-09-24 09:03AM	Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes (Zacks)
Apr-08-24 09:34AM	Labcorp (LH) Extends MRD Clinical Research With New Launch (Zacks)
07:09AM	Do You Think Laboratory Corporation of America Holdings (LH) Valuation is Not Attractive Anymore? (Insider Monkey)
07:03AM	Heres Why Vltava Fund Sold Lockheed Martin Corporation (LMT) (Insider Monkey)
07:00AM	Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs (PR Newswire)
Apr-05-24 07:00AM	Labcorp Launches Labcorp Plasma Detect Extending Leadership into Molecular Residual Disease (MRD) Clinical Research (PR Newswire)
Apr-03-24 11:01AM	Insider Sell: EVP, President Diagnostics & COO Mark Schroeder Sells Shares of Laboratory ... (GuruFocus.com)
11:00AM	Insider Sell: EVP, Chief Marketing Officer Amy Summy Sells 3,500 Shares of Laboratory Corp of ... (GuruFocus.com)
Apr-02-24 11:20AM	Here's Why Investors Should Retain Labcorp (LH) Stock for Now (Zacks)
07:00AM	Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research (PR Newswire)
Apr-01-24 12:42PM	Labcorp (LH) to Boost Clinical Diagnostics With New Deal (Zacks)
08:00AM	Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp (Business Wire)
Mar-30-24 01:30AM	Insider Sell: EVP, Chief Legal Officer van der Vaart Sandra D Sells 3,553 Shares of Laboratory ... (GuruFocus.com)
Mar-29-24 09:00AM	The Prelude Network Names Labcorp Its Preferred Genetic Carrier Screening Lab (PR Newswire)
Mar-28-24 11:08PM	Labcorp inks $237.5M buyout of Opkos reproductive, womens health testing assets (MedTech Dive)
08:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business (PR Newswire)
Mar-27-24 07:00AM	Labcorp to Announce First Quarter Financial Results on April 25, 2024 (PR Newswire)
Mar-25-24 07:03AM	Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test (Zacks)
Mar-20-24 07:00AM	Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials (PR Newswire)
Mar-18-24 09:44AM	Labcorp (LH) Presents New Research on Precision Diagnostics (Zacks)
Mar-16-24 10:29AM	Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer (PR Newswire)
Mar-15-24 09:25AM	Labcorp (LH) Expands Strategic Alliances, Test Sales Fall (Zacks)
Mar-11-24 11:00AM	Insider Sell: EVP, President Diagnostics & COO Mark Schroeder Sells Shares of Laboratory ... (GuruFocus.com)
Mar-08-24 10:26AM	Labcorp (LH) Introduces Weight Loss Management Portfolio (Zacks)
Mar-07-24 07:00AM	Labcorp Launches Weight Loss Management Testing Solutions (PR Newswire)
Mar-05-24 07:00AM	PINNACLE FERTILITY PARTNERS WITH LABCORP TO ENHANCE GENETIC TESTING SERVICES (PR Newswire)
Feb-27-24 12:08AM	Decoding Laboratory Corp of America Holdings (LH): A Strategic SWOT Insight (GuruFocus.com)
Feb-26-24 08:45AM	Here's Why Investors Should Hold Labcorp (LH) Stock for Now (Zacks)
05:01AM	Laboratory Corp of America Holdings's Dividend Analysis (GuruFocus.com)
Feb-21-24 12:00PM	Labcorp (LH) Moves to Buy: Rationale Behind the Upgrade (Zacks)
08:19AM	Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board (GlobeNewswire)
Feb-19-24 06:28AM	Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Revised) (Zacks)
Feb-16-24 09:41AM	Laboratory Corporation of America Holdings (NYSE:LH) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:15AM	Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Revised) (Zacks)
12:59AM	Q4 2023 Laboratory Corporation of America Holdings Earnings Call (Thomson Reuters StreetEvents)
Feb-15-24 03:29PM	Analyst Report: Laboratory Corporation of America Holdings (Morningstar Research)
12:48PM	Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall (Zacks)
09:30AM	Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:37AM	Laboratory Corp of America Holdings (LH) Reports Mixed Q4 and Full Year 2023 Results; Provides ... (GuruFocus.com)
07:35AM	Labcorp forecasts 2024 profit above estimates on strong testing demand (Reuters)
07:30AM	Labcorp: Q4 Earnings Snapshot (Associated Press Finance)
06:56AM	Labcorp Announces 2023 Fourth Quarter and Full Year Results (PR Newswire)
Feb-12-24 09:16AM	Labcorp (LH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Feb-08-24 10:00AM	Analysts Estimate Labcorp (LH) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:08AM	Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised) (Zacks)
Feb-07-24 09:05AM	Labcorp Elevates Employee Health Benefits with WeightWatchers for Business Full-Spectrum Weight Health Platform (GlobeNewswire)
Feb-05-24 08:16AM	Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-01-24 04:55PM	Labcorp (LH) Unveils Test for Preeclampsia in Pregnant Women (Zacks)
07:00AM	Labcorp Named One of the World's Most Admired Companies by FORTUNE Magazine (PR Newswire)
Jan-31-24 07:00AM	Labcorp Launches New Test for Risk Assessment and Prognosis of Severe Preeclampsia in Pregnant Women (PR Newswire)
Jan-16-24 06:58AM	Labcorp to Announce Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 (PR Newswire)
Jan-12-24 06:57AM	Labcorp Declares Quarterly Dividend (PR Newswire)
Jan-11-24 11:21AM	LabCorp (LH) to Expand Clinical Trails Access With New Pact (Zacks)
Jan-10-24 08:02AM	Labcorp and Hawthorne Effect Collaborate to Bring Clinical Trials Directly to Patients and Investigators in Local Communities (PR Newswire)
Jan-05-24 04:45AM	Here's How Vltava Fund Created Value Via Laboratory Corporation of America Holdings (LH) Spin-off (Insider Monkey)
Jan-02-24 07:00AM	Labcorp to Speak at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-29-23 09:23AM	Here's Why Investors Should Retain Labcorp (LH) Stock for Now (Zacks)
Dec-26-23 03:59PM	SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure (PR Newswire)
Dec-21-23 09:03AM	Should You Invest in Laboratory Corporation of America Holdings (LH)? (Insider Monkey)
Dec-17-23 05:05AM	11 Recent Spin-off Companies That Hedge Funds Are Piling Into (Insider Monkey)
Nov-30-23 07:46PM	Analyst Report: Laboratory Corporation of America Holdings (Morningstar Research)
Nov-27-23 08:35AM	Here's Why Investors Should Retain Labcorp (LH) Stock for Now (Zacks)
Nov-24-23 07:21AM	Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal (Zacks)
Nov-22-23 05:04AM	Labcorp to lay off 239 workers in New Jersey amid biotech slump (MedTech Dive)
Nov-20-23 07:00AM	Labcorp and Legacy Health Finalize Comprehensive Laboratory Relationship (PR Newswire)
Nov-16-23 07:00AM	Tigerlily Foundation and Labcorp Launch I AM INCLUDED Framework to Increase Clinical Trial Diversity, Accelerate Delivery of Innovative Cancer Treatments (PR Newswire)

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ANDERSON KERRII B	Director	May 02 '24	Sale	200.10	250	50,025	15,722	May 02 04:29 PM
ANDERSON KERRII B	Director	Apr 30 '24	Sale	204.13	250	51,034	15,972	May 02 04:29 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	Apr 29 '24	Sale	204.33	2,439	498,358	2,087	May 01 06:29 PM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Apr 01 '24	Sale	217.29	6,477	1,407,387	5,036	Apr 03 08:35 AM
Summy Amy B.	EVP, Chief Marketing Officer	Apr 01 '24	Sale	217.29	3,500	760,515	3,975	Apr 03 08:34 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Mar 28 '24	Sale	216.74	3,553	770,077	7,637	Mar 29 05:54 PM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Mar 07 '24	Option Exercise	117.09	2,119	248,114	10,084	Mar 11 08:59 AM
Schroeder Mark S	EVP, Pres Diagnostics & COO	Mar 07 '24	Sale	218.45	5,048	1,102,736	5,036	Mar 11 08:59 AM
Summy Amy B.	EVP, Chief Marketing Officer	Mar 07 '24	Sale	218.45	227	49,588	3,859	Mar 11 08:56 AM
EISENBERG GLENN A	Chief Financial Officer, EVP	Feb 21 '24	Option Exercise	163.63	14,054	2,299,656	58,099	Feb 22 03:05 PM
EISENBERG GLENN A	Chief Financial Officer, EVP	Feb 21 '24	Sale	215.97	34,504	7,451,866	23,595	Feb 22 03:05 PM
DiVincenzo Jonathan P.	EVP, Pres, Central Labs & Intl	Feb 21 '24	Sale	215.49	500	107,745	3,401	Feb 22 03:04 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	Feb 13 '24	Sale	226.45	237	53,669	7,637	Feb 15 08:32 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Feb 08 '24	Sale	222.06	259	57,514	7,637	Feb 09 12:19 PM
van der Vaart Sandra D	EVP, Chief Legal Officer	Feb 05 '24	Sale	220.57	193	42,570	7,637	Feb 06 03:47 PM
Wilkinson Peter J	SVP, Chief Accounting Officer	Nov 16 '23	Sale	210.71	1,384	291,627	2,087	Nov 20 12:23 PM
ANDERSON KERRII B	Director	Aug 08 '23	Sale	211.57	5,000	1,057,832	15,275	Aug 10 08:55 AM
van der Vaart Sandra D	EVP, Chief Legal Officer	Jun 29 '23	Sale	240.00	212	50,880	7,605	Jul 03 11:52 AM
Kirchgraber Paul R	CEO, Covance Drug Development	May 19 '23	Option Exercise	182.51	4,300	784,793	17,246	May 23 08:06 AM
Kirchgraber Paul R	CEO, Covance Drug Development	May 19 '23	Sale	216.91	4,300	932,707	12,946	May 23 08:06 AM
Schroeder Mark S	EVP, Pres Diagnostics & COO	May 18 '23	Option Exercise	130.60	1,500	195,900	8,187	May 22 03:08 PM
Schroeder Mark S	EVP, Pres Diagnostics & COO	May 18 '23	Sale	216.77	1,500	325,155	6,687	May 22 03:08 PM

Open in Screener

VCYT

Veracyte Inc

May 03 • 04:00PM ET

20.35

Dollar change +0.16
Percentage change 0.79	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI VB ARKG IWM VXF VBK IWN ARKW IBB

Index	RUT	P/E	-	EPS (ttm)	-1.02	Insider Own	1.67%	Shs Outstand	75.07M	Perf Week	5.39%
Market Cap	1.53B	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-1.57%	Shs Float	73.81M	Perf Month	0.89%
Income	-74.40M	PEG	-	EPS next Q	-0.16	Inst Own	104.21%	Short Float	4.93%	Perf Quarter	-18.04%
Sales	361.05M	P/S	4.23	EPS this Y	74.73%	Inst Trans	0.36%	Short Ratio	5.28	Perf Half Y	-3.37%
Book/sh	14.25	P/B	1.43	EPS next Y	84.39%	ROA	-6.40%	Short Interest	3.64M	Perf Year	-5.44%
Cash/sh	2.88	P/C	7.06	EPS next 5Y	-	ROE	-7.02%	52W Range	18.61 - 30.52	Perf YTD	-26.03%
Dividend Est.	-	P/FCF	44.59	EPS past 5Y	-10.52%	ROI	-7.08%	52W High	-33.32%	Beta	1.70
Dividend TTM	-	Quick Ratio	4.40	Sales past 5Y	34.42%	Gross Margin	61.81%	52W Low	9.35%	ATR (14)	0.88
Dividend Ex-Date	-	Current Ratio	4.66	EPS Y/Y TTM	-99.73%	Oper. Margin	-3.22%	RSI (14)	50.02	Volatility	4.94% 4.02%
Employees	815	Debt/Eq	0.01	Sales Y/Y TTM	21.76%	Profit Margin	-20.61%	Recom	1.89	Target Price	30.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-623.36%	Payout	-	Rel Volume	0.67	Prev Close	20.19
Sales Surprise	6.77%	EPS Surprise	-288.45%	Sales Q/Q	22.29%	Earnings	May 07 AMC	Avg Volume	689.13K	Price	20.35
SMA20	2.18%	SMA50	-4.33%	SMA200	-15.50%	Trades		Volume	463,335	Change	0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Janney	Buy → Neutral
Aug-31-17	Resumed	BTIG Research	Buy	$13
Nov-14-16	Resumed	Leerink Partners	Outperform	$12
Dec-18-15	Initiated	Cantor Fitzgerald	Buy	$13
Jun-11-15	Reiterated	Leerink Partners	Outperform	$11 → $13

Show Previous Ratings

Apr-22-24 05:00PM	Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
08:30AM	New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance (Business Wire)
Apr-16-24 08:30AM	Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 (Business Wire)
Apr-02-24 10:33AM	What Makes Veracyte (VCYT) a Lucrative Investment? (Insider Monkey) -5.22%
Feb-27-24 05:55PM	Veracytes Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Business Wire)
03:20PM	Loading…
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +6.22%
Feb-23-24 11:10AM	Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.87%
07:43AM	Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands (Zacks)
07:37AM	Q4 2023 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook (GuruFocus.com)
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-21-24 05:00PM	Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference (Business Wire)
Feb-08-24 08:00AM	Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 (Business Wire)
08:15AM	Loading…
Feb-06-24 08:15AM	Veracyte Completes Acquisition of C2i Genomics (Business Wire)
Jan-08-24 08:00AM	Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform (Business Wire) +13.10%
Dec-12-23 04:30PM	Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-01-23 04:05PM	Real-World Data Presented at SUO 2023 Show that Veracytes Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress (Business Wire)
Nov-29-23 08:30AM	Clinical Validation Data Published in CHEST Demonstrate that Veracytes Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules (Business Wire)
Nov-22-23 08:30AM	Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Business Wire)
Nov-08-23 04:39PM	Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:57PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2023 Financial Results (Business Wire)
04:00PM	Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally (Business Wire)
Nov-02-23 08:15AM	Veracyte to Participate in the Stephens Annual Investment Conference (Business Wire) +6.13%
Oct-27-23 08:30AM	Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Business Wire)
Oct-26-23 02:50PM	7 Undervalued Stocks That Analysts Love Right Now (InvestorPlace)
Oct-17-23 08:15AM	Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
09:00AM	Loading…
Oct-12-23 09:00AM	New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracytes Envisia Genomic Classifier for Patients with Interstitial Lung Disease (Business Wire) -5.82%
Oct-04-23 04:05PM	New Data from Phase 3 Trial Further Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Sep-28-23 04:05PM	New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracytes Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer (Business Wire)
08:15AM	Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 (Business Wire)
Sep-27-23 09:00AM	Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Business Wire)
Sep-21-23 04:05PM	Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Companys Tests (Business Wire)
Sep-06-23 08:15AM	Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies (Business Wire)
Sep-02-23 06:15AM	Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? (Motley Fool)
Aug-29-23 08:15AM	Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-22-23 08:15AM	Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Business Wire)
Aug-15-23 04:15PM	Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego (Business Wire)
Aug-08-23 06:05PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:55PM	Veracyte: Q2 Earnings Snapshot (AP Finance)
04:05PM	Veracyte Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 08:15AM	Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracytes Decipher Prostate Genomic Classifier in Prostate Cancer Treatment (Business Wire)
Jul-19-23 05:00PM	Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jun-20-23 08:31AM	New Data Suggest Veracytes Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer (Business Wire)
Jun-12-23 08:31AM	Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023 (Business Wire)
May-30-23 06:56AM	Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-25-23 05:13PM	New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracytes Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer (Business Wire)
May-24-23 09:00AM	New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracytes Genomic Tests in Interstitial Lung Disease and Lung Cancer (Business Wire)
May-23-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-22-23 07:30AM	Here's Why This Little-Known Growth Stock Is a Buy (Motley Fool) +7.79%
May-12-23 06:15AM	Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer (Business Wire)
May-05-23 01:59PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 06:25PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Veracyte Announces First Quarter 2023 Financial Results (Business Wire)
09:45AM	New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules (Business Wire)
May-03-23 05:44PM	New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients (Business Wire)
08:30AM	Veracyte Announces Release of Inaugural ESG Report (Business Wire)
May-02-23 04:05PM	Data Published in "The Red Journal" Validate Clinical Utility of Veracytes Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer (Business Wire) -8.23%
May-01-23 05:35PM	Three Abstracts Focusing on the Clinical Utility of Veracytes Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference (Business Wire)
Apr-29-23 04:31PM	Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Apr-27-23 04:05PM	Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting (Business Wire)
10:02AM	Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:55AM	Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High? (Zacks)
Apr-18-23 09:48AM	The five-year returns have been strong for Veracyte (NASDAQ:VCYT) shareholders despite underlying losses increasing (Simply Wall St.)
Apr-17-23 08:30AM	New Data Reinforce Ability of Veracytes Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification (Business Wire)
Apr-13-23 05:00PM	Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 (Business Wire) +7.24%
Apr-12-23 08:30AM	Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting (Business Wire)
Mar-23-23 06:54AM	Estimating The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT) (Simply Wall St.)
Mar-15-23 04:15PM	Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Companys Multi-Omics Capabilities and Tools for Biopharma Partners (Business Wire)
11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 12:11PM	Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank (Business Wire)
Mar-10-23 09:30AM	Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? (Motley Fool) -8.78%
Feb-27-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-23 05:42AM	We're Interested To See How Veracyte (NASDAQ:VCYT) Uses Its Cash Hoard To Grow (Simply Wall St.)
Feb-22-23 06:15PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.19%
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results (Business Wire)
Feb-15-23 08:36AM	Data Published in "The Red Journal" Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer (Business Wire)
Feb-13-23 05:23PM	New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment (Business Wire)
10:14AM	Stay Long and Strong: Billionaire Ken Fisher Snaps Up These 2 Strong Buy Stocks (TipRanks)
Feb-06-23 05:00PM	Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023 (Business Wire)
Feb-01-23 04:05PM	Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium (Business Wire)
08:32AM	Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules (Business Wire)
Jan-24-23 10:23AM	Better Long-Term Buy in 2023: Exact Sciences or Veracyte? (Motley Fool)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire) +5.75%
Jan-18-23 06:10AM	This Small-Cap Stock Is a No-Brainer Buy (Motley Fool)
Dec-22-22 08:54AM	Terex and Armstrong World Industries have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Dec-21-22 09:08AM	3 Medical Instruments Stocks on Recovery Path After Dismal 2022 (Zacks)
Dec-15-22 04:05PM	Data Published in JCEM Demonstrate Strong Real-World Performance of Veracytes Afirma GSC in Thyroid Cancer Diagnosis (Business Wire)
Dec-12-22 12:00PM	What Makes Veracyte (VCYT) a New Buy Stock (Zacks) +8.99%
Dec-01-22 02:46PM	Veracyte Stock Showing Market Leadership; Earns 93 RS Rating (Investor's Business Daily)
Nov-09-22 06:15AM	Veracyte Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) -7.49%
Nov-02-22 06:55PM	Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.57%
04:05PM	Veracyte Announces Third Quarter 2022 Financial Results (Business Wire)
Nov-01-22 05:11PM	Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting (Business Wire)
Oct-27-22 05:00PM	Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference (Business Wire)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EASTHAM KARIN	Director	Apr 01 '24	Option Exercise	13.19	10,000	131,900	43,125	Apr 02 04:17 PM
EASTHAM KARIN	Director	Apr 01 '24	Sale	21.65	10,000	216,528	33,125	Apr 02 04:17 PM
JONES EVAN/ FA	Director	Mar 01 '24	Option Exercise	13.19	10,000	131,900	47,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Mar 01 '24	Sale	24.36	10,000	243,599	37,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.17	3,090	93,232	35,173	Jul 24 05:06 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.14	838	25,257	37,601	Jul 24 05:06 PM
BISHOP JOHN L	Director	Jul 18 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
BISHOP JOHN L	Director	Jul 18 '23	Sale	30.50	10,000	305,000	33,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.19	7,441	224,616	38,263	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.16	2,324	70,090	38,439	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	23,949	720,106	45,704	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	19,095	574,106	40,763	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Sale	30.00	10,000	300,002	33,125	Jul 19 08:35 PM
Bhanji Muna	Director	Jun 16 '23	Sale	26.44	5,893	155,786	28,514	Jun 21 04:55 PM
Bhanji Muna	Director	May 30 '23	Sale	25.91	1,539	39,875	24,733	Jun 01 05:06 PM

Open in Screener

SERA

Sera Prognostics Inc

May 03 • 04:00PM ET

10.85

Dollar change +0.22
Percentage change 2.07	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

SERA Sera Prognostics Inc daily Stock Chart

Held by: DWAS VTI VXF IWC AVSC DFAS DFAC

Index	-	P/E	-	EPS (ttm)	-1.16	Insider Own	45.15%	Shs Outstand	30.74M	Perf Week	0.93%
Market Cap	353.38M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	-1.67%	Shs Float	17.86M	Perf Month	15.67%
Income	-36.24M	PEG	-	EPS next Q	-0.27	Inst Own	34.75%	Short Float	1.31%	Perf Quarter	41.64%
Sales	0.31M	P/S	1139.95	EPS this Y	13.06%	Inst Trans	0.26%	Short Ratio	1.16	Perf Half Y	523.56%
Book/sh	2.21	P/B	4.90	EPS next Y	3.55%	ROA	-34.23%	Short Interest	0.23M	Perf Year	214.49%
Cash/sh	1.51	P/C	7.20	EPS next 5Y	-	ROE	-42.86%	52W Range	1.52 - 12.35	Perf YTD	81.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.21%	ROI	-51.05%	52W High	-12.18%	Beta	1.34
Dividend TTM	-	Quick Ratio	2.51	Sales past 5Y	109.61%	Gross Margin	-379.08%	52W Low	613.82%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	2.51	EPS Y/Y TTM	18.61%	Oper. Margin	-12980.72%	RSI (14)	57.71	Volatility	9.29% 7.39%
Employees	57	Debt/Eq	0.03	Sales Y/Y TTM	14.18%	Profit Margin	-11843.79%	Recom	1.67	Target Price	2.75
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	19.70%	Payout	-	Rel Volume	0.24	Prev Close	10.63
Sales Surprise	-56.24%	EPS Surprise	3.10%	Sales Q/Q	-36.92%	Earnings	May 08 AMC	Avg Volume	202.14K	Price	10.85
SMA20	6.58%	SMA50	13.45%	SMA200	112.34%	Trades		Volume	48,858	Change	2.07%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-22	Downgrade	Citigroup	Buy → Neutral	$18 → $4
Nov-19-21	Initiated	Oppenheimer	Outperform	$19
Oct-15-21	Resumed	Cowen	Outperform

Apr-29-24 02:15PM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024 (PR Newswire)
Mar-29-24 01:32AM	Chief Scientific Officer John Boniface Sells 77,136 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
Mar-27-24 01:27AM	Chief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA) (GuruFocus.com)
Mar-25-24 12:00PM	Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know (Zacks) -8.50%
Mar-21-24 09:57AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:54PM	Loading…
Mar-20-24 08:54PM	SERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:33PM	Sera Prognostics Inc Reports Modest Revenue Growth Amid Operational Streamlining (GuruFocus.com)
05:20PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey)
Mar-04-24 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024 (PR Newswire)
Feb-29-24 11:14AM	Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Dec-11-23 12:00PM	Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy (Zacks)
Dec-06-23 01:19PM	Why Is Sera Prognostics (SERA) Stock Up 260% Today? (InvestorPlace) +161.43%
08:30AM	SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS (PR Newswire)
01:00PM	Loading…
Nov-22-23 01:00PM	SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE (PR Newswire)
Nov-12-23 10:59AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:29PM	Sera Prognostics Inc (SERA) Reports Q3 2023 Financial Results: Revenue Declines as Cost ... (GuruFocus.com)
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Oct-25-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023 (PR Newswire) +6.06%
Sep-21-23 08:30AM	SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023 (PR Newswire)
Aug-31-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -6.32%
Aug-30-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-09-23 05:50PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Jul-31-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023 (PR Newswire)
May-25-23 04:15PM	Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue (PR Newswire) -5.08%
May-15-23 05:15PM	Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO (PR Newswire)
May-10-23 06:05PM	Sera Prognostics, Inc. (SERA) Reports Q1 Loss (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
07:31AM	Loading…
May-04-23 07:31AM	We're Not Very Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate (Simply Wall St.)
Apr-27-23 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023 (PR Newswire)
Apr-24-23 09:35AM	Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-27-23 12:00PM	All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy (Zacks)
02:27AM	Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 06:29AM	Sera Prognostics Full Year 2022 Earnings: Revenues Miss Expectations (Simply Wall St.)
Mar-22-23 05:35PM	Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Mar-09-23 04:05PM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023 (PR Newswire)
Feb-23-23 04:20PM	SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES (PR Newswire)
Feb-18-23 07:43AM	Individual investors in Sera Prognostics, Inc. (NASDAQ:SERA) are its biggest bettors, and their bets paid off as stock gained 179% last week (Simply Wall St.)
Feb-15-23 08:30AM	Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL (PR Newswire) +73.28%
Nov-29-22 08:30AM	FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS (PR Newswire) -7.63%
Nov-15-22 08:30AM	SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS (PR Newswire)
Nov-09-22 06:15PM	Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Nov-04-22 04:00PM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9 (PR Newswire)
Oct-04-22 08:30AM	SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS (PR Newswire) +7.78%
Sep-22-22 08:30AM	BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS (PR Newswire)
Sep-20-22 07:19AM	Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-11-22 07:00AM	Sera Prognostics, Inc. (SERA) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-10-22 05:55PM	Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.64%
04:05PM	SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Aug-03-22 10:00AM	Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-28-22 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10 (PR Newswire)
Jun-06-22 02:15PM	SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE (PR Newswire)
May-19-22 04:15PM	SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE (PR Newswire)
May-18-22 03:03PM	SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING (PR Newswire)
May-10-22 04:05PM	SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
May-05-22 08:30AM	SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUITY THROUGH THE "EVERY MOTHER, EVERY BABY" PROJECT (PR Newswire)
May-02-22 08:30AM	Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10 (PR Newswire)
Apr-12-22 08:30AM	SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD (PR Newswire) -11.31%
Mar-30-22 07:30AM	Sera Prognostics, Inc. (SERA) Q4 2021 Earnings Call Transcript (Motley Fool) -7.65%
Mar-29-22 04:00PM	SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS (PR Newswire) +12.19%
Mar-18-22 12:00PM	Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting (PR Newswire) -14.45%
07:00AM	Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29 (PR Newswire)
Mar-03-22 08:30AM	SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES (PR Newswire) -6.05%
Feb-17-22 08:30AM	SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE (PR Newswire)
Feb-07-22 08:30AM	SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES (PR Newswire)
Feb-01-22 08:30AM	SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST (PR Newswire)
Dec-15-21 08:30AM	SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX (PR Newswire)
Dec-02-21 08:00AM	Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth (PR Newswire)
Dec-01-21 11:40AM	Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-U.S. Populations (PR Newswire)
Nov-30-21 08:00AM	Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board (PR Newswire)
Nov-10-21 09:01AM	Sera Prognostics, Inc. (SERA) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-09-21 04:01PM	Sera Prognostics Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-08-21 04:20PM	Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board (PR Newswire)
Nov-04-21 08:00AM	Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs (PR Newswire) +5.63%
Nov-03-21 08:00AM	Sera Prognostics Announces Publication of the Clinical Validation of PreTRM® Threshold for Clinical Action (PR Newswire)
Nov-02-21 08:00AM	Sera Prognostics Announces Collaboration To Help Underserved Communities Make Informed Decisions About Prenatal Health (PR Newswire)
Oct-27-21 08:30AM	Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9 (PR Newswire)
Oct-15-21 10:59AM	We're Not Very Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate (Simply Wall St.)
Sep-28-21 08:30AM	Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer (GlobeNewswire)
Sep-20-21 08:30AM	Sera Prognostics to be Added to Russell 2000 Index (GlobeNewswire)
Sep-15-21 08:00AM	Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer (GlobeNewswire) -6.73%
Sep-14-21 08:00AM	Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health (GlobeNewswire)
Sep-13-21 08:00AM	Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit (GlobeNewswire)
Aug-30-21 04:05PM	Sera Prognostics Reports Second Quarter 2021 Financial Results (GlobeNewswire) -6.60%
Aug-17-21 08:00AM	Sera Prognostics PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility (GlobeNewswire)
Jul-14-21 09:03PM	Sera Prognostics Announces Pricing of Initial Public Offering (GlobeNewswire)

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boniface John J.	Chief Scientific Officer	Mar 28 '24	Option Exercise	0.91	24,474	22,271	164,245	Mar 28 05:56 PM
Boniface John J.	Chief Scientific Officer	Mar 28 '24	Sale	9.04	24,474	221,245	139,771	Mar 28 05:56 PM
Boniface John J.	Chief Scientific Officer	Mar 27 '24	Option Exercise	0.91	48,909	44,507	188,680	Mar 28 05:56 PM
Boniface John J.	Chief Scientific Officer	Mar 27 '24	Sale	9.62	52,662	506,608	139,771	Mar 28 05:56 PM
Lindgardt Zhenya	Chief Executive Officer	Mar 26 '24	Sale	9.37	38,899	364,484	908,104	Mar 26 08:00 PM
Boniface John J.	Chief Scientific Officer	Mar 26 '24	Sale	9.55	21,438	204,733	143,524	Mar 26 05:38 PM
Aerts Austin	Chief Financial Officer	Mar 26 '24	Sale	9.37	8,092	75,822	322,488	Mar 26 08:00 PM
Boniface John J.	Chief Scientific Officer	Mar 25 '24	Sale	9.10	22,163	201,683	164,962	Mar 26 04:20 PM
Harrison Robert Gardner	Chief Information Officer	Mar 06 '24	Sale	9.02	2,138	19,285	145,697	Mar 07 04:15 PM
Jackson Benjamin	General Counsel	Mar 06 '24	Sale	9.02	1,856	16,741	150,179	Mar 07 04:15 PM
Boniface John J.	Chief Scientific Officer	Mar 06 '24	Sale	9.02	1,664	15,009	187,125	Mar 07 04:16 PM
Kearney Paul	Chief Data Officer	Mar 06 '24	Sale	9.02	1,028	9,273	159,038	Mar 07 04:16 PM
Aerts Austin	Chief Financial Officer	Mar 06 '24	Sale	9.02	444	4,005	330,580	Mar 07 04:16 PM
Lindgardt Zhenya	Chief Executive Officer	Feb 06 '24	Sale	8.03	27,997	224,816	947,003	Feb 07 04:56 PM
Aerts Austin	Chief Financial Officer	Feb 06 '24	Sale	8.03	9,786	78,582	331,024	Feb 07 04:56 PM
Boniface John J.	Chief Scientific Officer	Feb 06 '24	Sale	8.03	5,665	45,490	188,789	Feb 07 04:57 PM
Jackson Benjamin	General Counsel	Feb 06 '24	Sale	8.03	5,665	45,490	152,035	Feb 07 04:57 PM
Harrison Robert Gardner	Chief Information Officer	Feb 06 '24	Sale	8.03	5,665	45,490	147,835	Feb 07 04:56 PM
Kearney Paul	Chief Data Officer	Feb 06 '24	Sale	8.03	4,984	40,022	160,066	Feb 07 04:56 PM
Jackson Benjamin	General Counsel	Dec 07 '23	Sale	5.22	10,000	52,200	157,700	Dec 07 09:35 PM
Boniface John J.	Chief Scientific Officer	Dec 07 '23	Sale	4.80	5,000	24,000	194,454	Dec 07 09:35 PM
Harrison Robert Gardner	Chief Information Officer	Jun 05 '23	Sale	3.23	5,000	16,150	28,500	Jun 06 04:07 PM

Open in Screener

GH

Guardant Health Inc

May 03 • 04:00PM ET

18.88

Dollar change +0.30
Percentage change 1.61	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

GH Guardant Health Inc daily Stock Chart

Held by: VTI VB IWM VXF VBK IWO XT SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-4.28	Insider Own	4.79%	Shs Outstand	121.63M	Perf Week	8.82%
Market Cap	2.30B	Forward P/E	-	EPS next Y	-3.02	Insider Trans	-0.07%	Shs Float	116.04M	Perf Month	4.02%
Income	-479.45M	PEG	-	EPS next Q	-0.87	Inst Own	92.67%	Short Float	8.24%	Perf Quarter	-14.92%
Sales	563.95M	P/S	4.08	EPS this Y	23.51%	Inst Trans	1.90%	Short Ratio	4.96	Perf Half Y	-27.97%
Book/sh	1.30	P/B	14.47	EPS next Y	7.83%	ROA	-28.23%	Short Interest	9.56M	Perf Year	-18.13%
Cash/sh	9.59	P/C	1.97	EPS next 5Y	27.80%	ROE	-438.13%	52W Range	15.81 - 41.06	Perf YTD	-30.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-8.88%	ROI	-32.30%	52W High	-54.02%	Beta	1.04
Dividend TTM	-	Quick Ratio	6.24	Sales past 5Y	49.27%	Gross Margin	59.59%	52W Low	19.42%	ATR (14)	1.06
Dividend Ex-Date	-	Current Ratio	6.54	EPS Y/Y TTM	33.21%	Oper. Margin	-99.80%	RSI (14)	55.17	Volatility	4.85% 5.43%
Employees	1779	Debt/Eq	8.53	Sales Y/Y TTM	25.45%	Profit Margin	-85.02%	Recom	1.43	Target Price	37.11
Option/Short	Yes / Yes	LT Debt/Eq	8.36	EPS Q/Q	-15.63%	Payout	-	Rel Volume	0.53	Prev Close	18.58
Sales Surprise	3.65%	EPS Surprise	-83.27%	Sales Q/Q	22.19%	Earnings	May 09 AMC	Avg Volume	1.93M	Price	18.88
SMA20	6.53%	SMA50	2.45%	SMA200	-27.34%	Trades		Volume	1,023,823	Change	1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-24	Resumed	Craig Hallum	Buy	$28
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform	$27
Sep-28-23	Initiated	Bernstein	Outperform	$34
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$40
Jul-05-23	Resumed	JP Morgan	Overweight	$65
May-26-23	Upgrade	Citigroup	Neutral → Buy	$28 → $40
May-05-23	Initiated	UBS	Buy	$40
Mar-09-23	Downgrade	Citigroup	Buy → Neutral	$60 → $33
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$36
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral	$65 → $50
Oct-19-22	Initiated	Craig Hallum	Buy	$88
Oct-06-22	Initiated	Stephens	Overweight	$99
Aug-25-22	Initiated	Credit Suisse	Outperform	$80
Jun-03-22	Initiated	Piper Sandler	Overweight	$65
Apr-28-22	Resumed	BTIG Research	Buy	$135 → $115
Feb-24-22	Reiterated	Wells Fargo	Overweight	$150 → $115
Feb-24-22	Reiterated	SVB Leerink	Outperform	$170 → $140
Feb-24-22	Reiterated	Stifel	Buy	$160 → $130

Show Previous Ratings

Apr-29-24 04:01PM	Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors (PR Newswire)
11:18AM	Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating (MT Newswires)
Apr-22-24 08:52AM	FDA Advisory Panel Review of Guardant Healths Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23 (Business Wire) +9.46%
Apr-18-24 04:05PM	Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-03-24 08:05AM	Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting (Business Wire) -5.24%
04:02PM	Loading…
Apr-02-24 04:02PM	Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales (Investor's Business Daily)
Apr-01-24 08:35AM	Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks. (InvestorPlace)
Mar-30-24 07:43PM	20 Foods To Reduce Cancer Risk (Insider Monkey)
Mar-13-24 05:09PM	A blood test for colon cancer performed well in a study, expanding options for screening (Associated Press Finance)
05:00PM	Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine (Business Wire)
Mar-06-24 04:30PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-24 05:30AM	New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap (Business Wire)
Feb-28-24 06:46PM	21 Countries that Have the Highest Rates of Cancer Deaths (Insider Monkey)
Feb-26-24 02:13AM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Feb-23-24 11:48AM	Guardant Health, Inc. (NASDAQ:GH) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.80%
07:00PM	Loading…
Feb-22-24 07:00PM	Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:20PM	Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:23PM	Guardant Health: Q4 Earnings Snapshot (Associated Press Finance)
04:38PM	Guardant Health Inc (GH) Reports 25% Revenue Growth in Full Year 2023 (GuruFocus.com)
04:05PM	Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook (Business Wire)
09:55AM	Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet (Zacks)
Feb-16-24 03:10AM	15 Best Hospitals for Cancer Treatment in the US (Insider Monkey)
Feb-15-24 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
10:00AM	Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-07-24 09:00AM	Cathie Wood Is Selling This Stock: Should You? (Motley Fool)
Feb-02-24 09:35AM	Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround (Zacks)
Feb-01-24 04:05PM	Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (Business Wire)
09:35AM	Guardant Health (GH) Loses -13.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-31-24 07:08PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Jan-30-24 09:02AM	Baillie Gifford Acquires New Stake in Guardant Health Inc (GuruFocus.com) -7.29%
09:25AM	Loading…
Jan-28-24 09:25AM	3 Stocks to Buy for the Age of Personalized Medicine (InvestorPlace)
Jan-17-24 08:05AM	Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence (Business Wire)
Jan-08-24 02:48PM	7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 (InvestorPlace)
09:00AM	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results (Business Wire)
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
02:30AM	Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa (Business Wire)
Jan-02-24 11:00AM	Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer (Business Wire)
Dec-21-23 09:00AM	Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford (Business Wire) +8.25%
Dec-20-23 04:07PM	Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst (Benzinga) -9.61%
04:05PM	Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-19-23 04:05PM	Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield Blood Test (Business Wire)
Dec-05-23 01:05AM	Insider Sell: CIO Kumud Kalia Divests 5,800 Shares of Guardant Health Inc (GuruFocus.com)
Dec-04-23 05:00AM	Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities (Business Wire)
Nov-30-23 08:05AM	Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection (Business Wire)
Nov-29-23 06:41PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Nov-15-23 04:05PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.82%
03:00AM	Guardant Health to Appeal Federal District Court Verdict (Business Wire)
Nov-12-23 07:00PM	Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea (PR Newswire)
Nov-08-23 11:03AM	Analyst Report: Guardant Health, Inc. (Morningstar Research) -9.81%
Nov-07-23 10:59AM	Guardant Health, Inc. (NASDAQ:GH) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.41%
08:21AM	Q3 2023 Guardant Health Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 06:30PM	Guardant Health (GH) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:32PM	Guardant Health Inc (GH) Reports 22% Revenue Growth for Q3 2023 (GuruFocus.com)
04:43PM	Guardant Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance (Business Wire)
Nov-03-23 08:00AM	Guardant Health to Participate in Upcoming November Investor Conferences (Business Wire) +6.62%
Oct-31-23 08:05AM	Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR Platform (Business Wire)
Oct-30-23 05:25AM	11 Best Immunotherapy Stocks To Buy Now (Insider Monkey)
Oct-23-23 03:45AM	First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer (Business Wire)
Oct-17-23 09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (PR Newswire)
Oct-16-23 04:05PM	Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023 (Business Wire)
Oct-11-23 09:53AM	1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years (Motley Fool)
Oct-10-23 05:18PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Oct-09-23 02:03AM	14 Best Cancer Stocks To Buy Now (Insider Monkey)
Oct-08-23 07:30AM	Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health? (Motley Fool)
Sep-29-23 08:23AM	Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains? (Zacks)
Sep-28-23 04:22PM	Why Guardant Health Stock Jumped 15% This Week (Motley Fool) +8.83%
11:25AM	Why Guardant Health Stock Popped Again Today (Motley Fool)
Sep-27-23 12:10PM	Guardant Health Inc (GH): A Deep Dive into Its Performance Potential (GuruFocus.com) +7.05%
11:40AM	Guardant Health (GH): A Potential Value Trap? (GuruFocus.com)
10:00AM	WW upgraded, Macy's downgraded: Wall Street's top analyst calls (The Fly)
Sep-22-23 11:45AM	Guardant Health (GH): A Hidden Value Trap? Unpacking the Risks and Rewards (GuruFocus.com)
Sep-18-23 12:12PM	Guardant Health Inc (GH): A Deep Dive into Its Performance Potential (GuruFocus.com)
Sep-15-23 06:44PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Sep-14-23 12:58PM	Guardant Health (GH) Stock: A Hidden Value Trap? Unpacking the Risks and Rewards (GuruFocus.com)
Sep-09-23 07:31PM	Guardant Health (GH) Stock: A Hidden Value Trap? Unpacking the Risks and Rewards (GuruFocus.com)
Sep-06-23 08:05AM	Guardant Health Receives Coverage for Guardant Reveal from Geisinger Health Plan (Business Wire)
Sep-05-23 08:05AM	Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations (Business Wire)
Sep-03-23 10:24PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Sep-01-23 03:46PM	Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test (Business Wire) -10.41%
Aug-31-23 04:05PM	Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-30-23 11:41AM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Aug-22-23 05:51PM	Wall Street Analysts Believe Guardant Health (GH) Could Rally 42.09%: Here's is How to Trade (Zacks)
Aug-17-23 04:05PM	Guardant Health to Host Investor Day on September 7, 2023 (Business Wire)
Aug-10-23 09:53AM	2 Cathie Wood Stocks to Buy and Hold for 10 Years (Motley Fool)
Aug-07-23 03:28PM	Guardant Health Stock Sees Renewed Technical Strength (Investor's Business Daily)
Aug-05-23 06:55AM	Guardant Health, Inc. (NASDAQ:GH) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-04-23 10:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research) +6.42%
Aug-03-23 10:46PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
05:45PM	Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:40PM	Guardant Health: Q2 Earnings Snapshot (AP Finance)
04:05PM	Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance (Business Wire)
Aug-01-23 04:05PM	Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research (Business Wire)
Jul-29-23 12:12AM	Guardant Health (GH) Reports Solid Q2 Results (Insider Monkey)
Jul-21-23 07:33AM	Further weakness as Guardant Health (NASDAQ:GH) drops 3.9% this week, taking three-year losses to 56% (Simply Wall St.)
Jul-20-23 08:05AM	Guardant Health receives first commercial payor coverage for Guardant Reveal test from Blue Cross and Blue Shield of Louisiana (Business Wire)
Jul-19-23 08:52AM	Viking Globals Performance, AUM, and Long-Term Stock Picks (Insider Monkey)
Jul-18-23 09:55AM	Does Guardant Health (GH) Have the Potential to Rally 39.77% as Wall Street Analysts Expect? (Zacks)
Jul-12-23 04:05PM	Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023 (Business Wire)
Jul-07-23 06:51AM	What Does Guardant Health, Inc.'s (NASDAQ:GH) Share Price Indicate? (Simply Wall St.)

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krognes Steve E.	Director	Apr 30 '24	Option Exercise	0.00	154	0	3,393	May 02 05:03 PM
Tariq Musa	Director	Apr 15 '24	Option Exercise	0.00	249	0	3,247	Apr 16 06:36 PM
Saia John G.	Chief Legal Officer	Apr 15 '24	Option Exercise	0.00	7,569	0	28,366	Apr 16 06:35 PM
POTTER MYRTLE S	Director	Apr 15 '24	Option Exercise	0.00	68	0	7,582	Apr 16 06:33 PM
Joyce Meghan V.	Director	Apr 04 '24	Option Exercise	0.00	67	0	4,588	Apr 05 06:29 PM
Saia John G.	Chief Legal Officer	Apr 01 '24	Option Exercise	0.00	974	0	22,305	Apr 02 06:09 PM
Kalia Kumud	Chief Information Officer	Apr 01 '24	Option Exercise	0.00	1,607	0	14,329	Apr 02 06:08 PM
Freeman Chris	Chief Commercial Officer	Apr 01 '24	Option Exercise	0.00	1,929	0	16,502	Apr 02 06:06 PM
EAGLE CRAIG	Chief Medical Officer	Apr 01 '24	Option Exercise	0.00	1,714	0	12,073	Apr 02 06:05 PM
Chudova Darya	Chief Technology Officer	Apr 01 '24	Option Exercise	0.00	1,340	0	36,831	Apr 02 06:04 PM
Krognes Steve E.	Director	Mar 31 '24	Option Exercise	0.00	154	0	3,239	Apr 01 05:25 PM
Talasaz AmirAli	Co-Chief Executive Officer	Mar 31 '24	Option Exercise	0.00	11,461	0	1,913,806	Apr 01 05:23 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Mar 31 '24	Option Exercise	0.00	11,461	0	2,097,470	Apr 01 05:20 PM
Kalia Kumud	Chief Information Officer	Mar 18 '24	Buy	17.82	2,187	38,963	12,722	Mar 19 05:29 PM
Tariq Musa	Director	Mar 15 '24	Option Exercise	0.00	2,998	0	2,998	Mar 18 06:16 PM
POTTER MYRTLE S	Director	Mar 15 '24	Option Exercise	0.00	68	0	7,514	Mar 18 06:14 PM
Bell Michael Brian	Chief Financial Officer	Mar 15 '24	Option Exercise	0.00	1,233	0	12,882	Mar 18 06:12 PM
Joyce Meghan V.	Director	Mar 04 '24	Option Exercise	0.00	66	0	4,621	Mar 05 08:01 PM
Joyce Meghan V.	Director	Mar 04 '24	Sale	19.05	100	1,905	4,521	Mar 05 08:01 PM
Saia John G.	Chief Legal Officer	Mar 01 '24	Option Exercise	0.00	263	0	21,439	Mar 04 06:39 PM
Merrill Amelia	SVP, People	Mar 01 '24	Option Exercise	0.00	158	0	27,540	Mar 04 06:37 PM
Kalia Kumud	Chief Information Officer	Mar 01 '24	Option Exercise	0.00	710	0	10,789	Mar 04 06:35 PM
Chudova Darya	Chief Technology Officer	Mar 01 '24	Option Exercise	0.00	316	0	35,621	Mar 04 06:34 PM
Krognes Steve E.	Director	Feb 29 '24	Option Exercise	0.00	154	0	3,085	Mar 01 05:08 PM
POTTER MYRTLE S	Director	Feb 15 '24	Option Exercise	0.00	69	0	7,446	Feb 16 07:10 PM
Joyce Meghan V.	Director	Feb 04 '24	Option Exercise	0.00	66	0	4,555	Feb 05 08:12 PM
Krognes Steve E.	Director	Jan 31 '24	Option Exercise	0.00	155	0	2,931	Feb 01 05:38 PM
Chudova Darya	Chief Technology Officer	Jan 16 '24	Option Exercise	8.80	6,626	58,309	35,305	Jan 16 07:44 PM
POTTER MYRTLE S	Director	Jan 15 '24	Option Exercise	0.00	68	0	7,377	Jan 16 07:43 PM
Bell Michael Brian	Chief Financial Officer	Jan 15 '24	Option Exercise	0.00	3,308	0	13,005	Jan 16 07:41 PM
Kalia Kumud	Chief Information Officer	Jan 07 '24	Option Exercise	0.00	5,376	0	12,250	Jan 08 07:45 PM
Joyce Meghan V.	Director	Jan 04 '24	Option Exercise	0.00	67	0	4,489	Jan 05 04:58 PM
Kalia Kumud	Chief Information Officer	Jan 01 '24	Option Exercise	0.00	1,607	0	7,533	Jan 03 07:48 PM
Freeman Chris	Chief Commercial Officer	Jan 01 '24	Option Exercise	0.00	1,928	0	15,207	Jan 03 07:45 PM
EAGLE CRAIG	Chief Medical Officer	Jan 01 '24	Option Exercise	0.00	1,714	0	11,062	Jan 03 07:44 PM
Saia John G.	Chief Legal Officer	Jan 01 '24	Option Exercise	0.00	974	0	21,576	Jan 03 07:51 PM
Merrill Amelia	SVP, People	Jan 01 '24	Option Exercise	0.00	482	0	27,580	Jan 03 07:49 PM
Chudova Darya	Chief Technology Officer	Jan 01 '24	Option Exercise	0.00	1,339	0	29,228	Jan 03 07:42 PM
Krognes Steve E.	Director	Dec 31 '23	Option Exercise	0.00	154	0	2,776	Jan 02 06:06 PM
Bell Michael Brian	Chief Financial Officer	Dec 15 '23	Option Exercise	0.00	1,233	0	10,124	Dec 18 05:37 PM
POTTER MYRTLE S	Director	Dec 15 '23	Option Exercise	0.00	69	0	7,309	Dec 18 05:39 PM
Joyce Meghan V.	Director	Dec 04 '23	Option Exercise	0.00	66	0	4,522	Dec 05 05:01 PM
Joyce Meghan V.	Director	Dec 04 '23	Sale	26.34	100	2,634	4,422	Dec 05 05:01 PM
Kalia Kumud	Chief Information Officer	Dec 01 '23	Option Exercise	0.00	710	0	12,079	Dec 04 06:25 PM
Chudova Darya	Chief Technology Officer	Dec 01 '23	Option Exercise	0.00	315	0	27,998	Dec 04 06:24 PM
Saia John G.	Chief Legal Officer	Dec 01 '23	Option Exercise	0.00	263	0	20,733	Dec 04 06:28 PM
Merrill Amelia	SVP, People	Dec 01 '23	Option Exercise	0.00	158	0	27,153	Dec 04 06:26 PM
Kalia Kumud	Chief Information Officer	Dec 01 '23	Sale	26.37	5,800	152,954	5,926	Dec 04 06:25 PM
Krognes Steve E.	Director	Nov 30 '23	Option Exercise	0.00	154	0	2,622	Dec 04 06:22 PM
Chudova Darya	Chief Technology Officer	Nov 15 '23	Option Exercise	8.80	4,000	35,200	27,683	Nov 16 05:04 PM
POTTER MYRTLE S	Director	Nov 15 '23	Option Exercise	0.00	68	0	7,240	Nov 16 05:02 PM
Joyce Meghan V.	Director	Nov 04 '23	Option Exercise	0.00	66	0	4,456	Nov 06 05:40 PM
Krognes Steve E.	Director	Oct 31 '23	Option Exercise	0.00	154	0	2,468	Nov 01 08:07 PM
POTTER MYRTLE S	Director	Oct 15 '23	Option Exercise	0.00	68	0	7,172	Oct 16 06:28 PM
Joyce Meghan V.	Director	Oct 04 '23	Option Exercise	0.00	67	0	4,390	Oct 05 06:02 PM
Merrill Amelia	SVP, People	Oct 01 '23	Option Exercise	0.00	1,928	0	27,662	Oct 02 05:24 PM
Kalia Kumud	Chief Information Officer	Oct 01 '23	Option Exercise	0.00	6,428	0	14,241	Oct 02 05:22 PM
Freeman Chris	Chief Commercial Officer	Oct 01 '23	Option Exercise	0.00	7,713	0	15,407	Oct 02 05:20 PM
EAGLE CRAIG	Chief Medical Officer	Oct 01 '23	Option Exercise	0.00	6,856	0	11,719	Oct 02 05:18 PM
Chudova Darya	Chief Technology Officer	Oct 01 '23	Option Exercise	0.00	5,356	0	25,536	Oct 02 05:16 PM
Saia John G.	Chief Legal Officer	Oct 01 '23	Option Exercise	0.00	3,895	0	21,817	Oct 02 05:25 PM
Krognes Steve E.	Director	Sep 30 '23	Option Exercise	0.00	155	0	2,314	Oct 02 05:14 PM
Chudova Darya	Chief Technology Officer	Sep 28 '23	Option Exercise	8.80	4,500	39,600	20,180	Sep 29 06:36 PM
POTTER MYRTLE S	Director	Sep 15 '23	Option Exercise	0.00	69	0	7,104	Sep 19 07:07 PM
Bell Michael Brian	Chief Financial Officer	Sep 15 '23	Option Exercise	0.00	1,233	0	9,318	Sep 19 07:04 PM
Kalia Kumud	Chief Information Officer	Sep 12 '23	Sale	32.59	2,125	69,254	7,813	Sep 13 07:11 PM
Merrill Amelia	SVP, People	Sep 09 '23	Option Exercise	0.00	1,047	0	26,097	Sep 11 05:57 PM
Kalia Kumud	Chief Information Officer	Sep 09 '23	Option Exercise	0.00	6,544	0	12,201	Sep 11 05:55 PM
Chudova Darya	Chief Technology Officer	Sep 09 '23	Option Exercise	0.00	2,908	0	16,686	Sep 11 05:52 PM
Joyce Meghan V.	Director	Sep 05 '23	Sale	35.01	100	3,501	4,323	Sep 06 05:46 PM
Joyce Meghan V.	Director	Sep 04 '23	Option Exercise	0.00	66	0	4,423	Sep 06 05:46 PM
Chudova Darya	Chief Technology Officer	Sep 01 '23	Option Exercise	0.00	316	0	13,888	Sep 05 04:59 PM
Saia John G.	Chief Legal Officer	Sep 01 '23	Option Exercise	0.00	263	0	18,315	Sep 05 04:56 PM
Merrill Amelia	SVP, People	Sep 01 '23	Option Exercise	0.00	158	0	25,105	Sep 05 04:54 PM
Kalia Kumud	Chief Information Officer	Sep 01 '23	Option Exercise	0.00	710	0	5,903	Sep 05 04:52 PM
Krognes Steve E.	Director	Aug 31 '23	Option Exercise	0.00	154	0	2,159	Sep 05 04:46 PM
POTTER MYRTLE S	Director	Aug 15 '23	Option Exercise	0.00	68	0	7,035	Aug 16 06:57 PM
Merrill Amelia	SVP, People	Aug 15 '23	Option Exercise	0.00	631	0	25,166	Aug 16 06:56 PM
Joyce Meghan V.	Director	Aug 04 '23	Option Exercise	0.00	66	0	4,357	Aug 07 05:13 PM
Chudova Darya	Chief Technology Officer	Aug 01 '23	Option Exercise	0.00	1,440	0	14,070	Sep 05 04:59 PM
Merrill Amelia	SVP, People	Aug 01 '23	Option Exercise	0.00	1,371	0	25,010	Aug 02 05:53 PM
Krognes Steve E.	Director	Jul 31 '23	Option Exercise	0.00	154	0	2,005	Aug 01 06:08 PM
POTTER MYRTLE S	Director	Jul 15 '23	Option Exercise	0.00	69	0	6,967	Jul 17 04:51 PM
Joyce Meghan V.	Director	Jul 04 '23	Option Exercise	0.00	67	0	4,291	Jul 05 05:01 PM
Krognes Steve E.	Director	Jun 30 '23	Option Exercise	0.00	1,851	0	1,851	Jul 05 04:59 PM
Freeman Chris	Chief Commercial Officer	Jun 15 '23	Option Exercise	0.00	4,879	0	9,040	Jun 16 06:16 PM
Bell Michael Brian	Chief Financial Officer	Jun 15 '23	Option Exercise	0.00	1,233	0	8,512	Jun 16 06:14 PM
POTTER MYRTLE S	Director	Jun 15 '23	Option Exercise	0.00	68	0	6,898	Jun 16 06:12 PM
Joyce Meghan V.	Director	Jun 15 '23	Sale	37.55	2,766	103,863	4,224	Jun 16 06:06 PM
Joyce Meghan V.	Director	Jun 14 '23	Option Exercise	0.00	5,531	0	6,990	Jun 16 06:06 PM
Gadde Vijaya	Director	Jun 14 '23	Option Exercise	0.00	5,531	0	12,048	Jun 16 06:05 PM
CLARK IAN T	Director	Jun 14 '23	Option Exercise	0.00	6,703	0	8,901	Jun 16 06:03 PM
POTTER MYRTLE S	Director	Jun 14 '23	Option Exercise	0.00	5,531	0	6,830	Jun 16 06:12 PM
Kaul Samir	Director	Jun 14 '23	Option Exercise	0.00	5,531	0	11,404	Jun 16 06:08 PM
Kalia Kumud	Chief Information Officer	Jun 09 '23	Buy	32.71	2,981	97,498	5,193	Jun 13 05:42 PM
Joyce Meghan V.	Director	Jun 04 '23	Option Exercise	0.00	66	0	1,459	Jun 05 05:50 PM
Kalia Kumud	Chief Information Officer	Jun 01 '23	Option Exercise	0.00	710	0	2,458	Jun 05 05:45 PM
Saia John G.	Chief Legal Officer	Jun 01 '23	Option Exercise	0.00	263	0	18,143	Jun 05 05:49 PM
Merrill Amelia	SVP, People	Jun 01 '23	Option Exercise	0.00	158	0	23,694	Jun 05 05:47 PM
Chudova Darya	Chief Technology Officer	Jun 01 '23	Option Exercise	0.00	316	0	12,740	Sep 05 04:59 PM

Open in Screener

XGN

Exagen Inc

May 03 • 04:00PM ET

1.40

Dollar change +0.01
Percentage change 1.08	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	53.72%	Shs Outstand	17.05M	Perf Week	-0.86%
Market Cap	24.14M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	-0.21%	Shs Float	7.98M	Perf Month	-7.89%
Income	-23.69M	PEG	-	EPS next Q	-0.36	Inst Own	38.06%	Short Float	0.15%	Perf Quarter	-33.65%
Sales	52.55M	P/S	0.46	EPS this Y	-1.86%	Inst Trans	-0.85%	Short Ratio	0.36	Perf Half Y	-19.08%
Book/sh	1.33	P/B	1.05	EPS next Y	27.39%	ROA	-32.77%	Short Interest	0.01M	Perf Year	-45.10%
Cash/sh	2.12	P/C	0.66	EPS next 5Y	-	ROE	-72.72%	52W Range	1.30 - 3.92	Perf YTD	-29.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.69%	ROI	-53.01%	52W High	-64.31%	Beta	1.20
Dividend TTM	-	Quick Ratio	3.78	Sales past 5Y	10.63%	Gross Margin	56.06%	52W Low	7.67%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	4.02	EPS Y/Y TTM	51.64%	Oper. Margin	-43.46%	RSI (14)	41.27	Volatility	4.86% 5.24%
Employees	179	Debt/Eq	1.05	Sales Y/Y TTM	15.33%	Profit Margin	-45.08%	Recom	1.33	Target Price	5.50
Option/Short	Yes / Yes	LT Debt/Eq	0.97	EPS Q/Q	62.57%	Payout	-	Rel Volume	0.31	Prev Close	1.38
Sales Surprise	19.12%	EPS Surprise	27.99%	Sales Q/Q	7.23%	Earnings	May 13 BMO	Avg Volume	33.47K	Price	1.40
SMA20	-1.85%	SMA50	-14.15%	SMA200	-28.45%	Trades		Volume	10,425	Change	1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Oct-15-21	Resumed	Cowen	Outperform	$26
Apr-15-21	Initiated	Canaccord Genuity	Buy	$25
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$32
Oct-08-20	Initiated	BTIG Research	Buy	$18
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight	$19 → $20
Oct-14-19	Initiated	William Blair	Outperform
Oct-14-19	Initiated	Cowen	Outperform	$17
Oct-14-19	Initiated	Cantor Fitzgerald	Overweight	$18

Apr-30-24 04:05PM	Exagen to Announce First Quarter 2024 Results on May 13, 2024 (GlobeNewswire)
Apr-26-24 08:30AM	Exagen Inc. Announces Changes to the Board of Directors (GlobeNewswire)
Mar-19-24 09:37AM	Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.99%
01:55AM	Q4 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 12:52PM	XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +9.26%
09:25AM	Loading…
09:25AM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Mar-08-24 09:00AM	Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-07-24 04:05PM	Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024 (GlobeNewswire)
Feb-06-24 08:50AM	Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock (Zacks)
Jan-30-24 04:05PM	Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-07-24 12:00PM	Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance (GlobeNewswire)
Nov-13-23 04:05PM	Exagen Inc. Reports Strong Third Quarter 2023 Results (GlobeNewswire)
Nov-09-23 04:05PM	Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers (GlobeNewswire) -6.25%
Nov-02-23 04:05PM	Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
04:05PM	Loading…
Oct-30-23 04:05PM	Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire) +6.75%
Sep-28-23 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting (GlobeNewswire)
Sep-12-23 04:05PM	Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-09-23 10:47AM	Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript (Insider Monkey) -7.22%
Aug-08-23 04:13AM	Q2 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 09:15AM	Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.76%
08:00AM	Exagen Inc. Reports Strong Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 04:05PM	Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire) -6.51%
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
07:33AM	This Exagen Insider Increased Their Holding In The Last Year (Simply Wall St.)
Jun-13-23 08:19AM	Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement (Simply Wall St.) -8.36%
May-30-23 09:00AM	Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference (GlobeNewswire)
May-17-23 07:11AM	Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years (Simply Wall St.) -6.90%
May-16-23 11:03AM	Q1 2023 Exagen Inc Earnings Call (Thomson Reuters StreetEvents) +19.51%
05:55PM	Loading…
May-15-23 05:55PM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-01-23 04:05PM	Exagen Announces Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-24-23 04:05PM	Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Mar-24-23 08:16AM	Exagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 06:12AM	Exagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Mar-21-23 07:40AM	Q4 2022 Exagen Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-23 05:25PM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-06-23 04:05PM	Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023 (GlobeNewswire) +5.31%
Feb-27-23 09:00AM	Exagen Inc. to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-14-23 06:19AM	Exagen Inc. (NASDAQ:XGN) insider upped their holding earlier this year (Simply Wall St.)
Jan-30-23 04:05PM	Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire)
Nov-14-22 07:55PM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.49%
04:05PM	Exagen Inc. Reports Third Quarter 2022 Results (GlobeNewswire)
Nov-08-22 04:05PM	Exagen Inc. to Participate in Fourth Quarter Investor Conferences (GlobeNewswire)
Oct-31-22 04:05PM	Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Oct-17-22 09:00AM	Exagen Announces Appointment of John Aballi as CEO (GlobeNewswire)
Oct-04-22 08:25AM	Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer (GlobeNewswire)
Sep-20-22 04:05PM	Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting (GlobeNewswire)
Sep-19-22 10:20AM	The past three years for Exagen (NASDAQ:XGN) investors has not been profitable (Simply Wall St.) -8.67%
Sep-01-22 04:05PM	Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients (GlobeNewswire)
Aug-05-22 12:00PM	Exagen Inc. (XGN) Q2 2022 Earnings Call Transcript (Motley Fool) -23.61%
Aug-04-22 06:55PM	Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:06PM	Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA (GlobeNewswire)
04:05PM	Exagen Inc. Reports Second Quarter 2022 Results (GlobeNewswire)
Jul-25-22 04:05PM	Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire) +8.23%
Jul-21-22 04:05PM	Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-05-22 08:25AM	Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility (GlobeNewswire)
Jun-21-22 08:10AM	Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet? (Simply Wall St.) +8.65%
Jun-09-22 08:25AM	Exagen Inc. Expands Coverage with MediNcrease (GlobeNewswire) +10.78%
May-26-22 04:05PM	Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference (GlobeNewswire) +9.50%
May-16-22 04:05PM	Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus (GlobeNewswire)
May-11-22 05:55PM	Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -16.16%
04:06PM	Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test (GlobeNewswire)
04:05PM	Exagen Inc. Reports First Quarter 2022 Results (GlobeNewswire)
May-10-22 10:45AM	AdaptHealth Corp. (AHCO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.25%
May-03-22 05:15PM	MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-01-22 12:00PM	Exagen Announces Five-Week Campaign for Lupus Awareness Month (GlobeNewswire)
Apr-25-22 04:05PM	Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022 (GlobeNewswire)
Apr-20-22 04:05PM	Exagen Inc. to Participate in Investor Summit Groups Q2 Conference (GlobeNewswire)
Apr-12-22 07:22AM	Shareholders in Exagen (NASDAQ:XGN) have lost 61%, as stock drops 15% this past week (Simply Wall St.)
Mar-30-22 08:25AM	Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems (GlobeNewswire)
Mar-22-22 10:00PM	Exagen Inc. (XGN) Q4 2021 Earnings Call Transcript (Motley Fool)
05:25PM	Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives (GlobeNewswire)
04:05PM	Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results (GlobeNewswire)
Mar-16-22 04:05PM	Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board (GlobeNewswire) +6.52%
Mar-09-22 05:35PM	Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +13.31%
04:05PM	Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum (GlobeNewswire)
Mar-08-22 04:05PM	Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022 (GlobeNewswire)
Mar-07-22 08:05AM	Eagle Pharmaceuticals (EGRX) Lags Q4 Earnings and Revenue Estimates (Zacks)
Feb-24-22 05:40PM	MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-08-22 02:38PM	Samjo Capital LLC Buys RumbleON Inc, Iteris Inc, Thryv Holdings Inc, Sells GAN, Exagen Inc, ... (GuruFocus.com)
Feb-02-22 04:05PM	Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire) -7.49%
Jan-12-22 10:46AM	Health Check: How Prudently Does Exagen (NASDAQ:XGN) Use Debt? (Simply Wall St.)
Jan-09-22 12:00PM	Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection (GlobeNewswire)
Nov-17-21 04:05PM	Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-11-21 08:30AM	Exagen Inc. (XGN) Q3 2021 Earnings Call Transcript (Motley Fool) +6.21%
Nov-10-21 05:55PM	Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.02%
04:05PM	Exagen Inc. Reports Third Quarter 2021 Results (GlobeNewswire)
Nov-04-21 04:05PM	Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum (GlobeNewswire)
Nov-03-21 03:01PM	Earnings Preview: Exagen Inc. (XGN) Q3 Earnings Expected to Decline (Zacks)
Oct-27-21 04:05PM	Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021 (GlobeNewswire)
08:25AM	Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus (GlobeNewswire)
Oct-25-21 08:25AM	Exagen Inc. Announces $27.2 Million Debt Refinancing (GlobeNewswire)
Oct-21-21 04:05PM	Exagen Showcases Eight Scientific Presentations at ACRs Virtual Annual Meeting in November 2021 (GlobeNewswire)
Oct-13-21 11:05AM	The past year for Exagen (NASDAQ:XGN) investors has not been profitable (Simply Wall St.)
Sep-13-21 04:15PM	Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference (GlobeNewswire)

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adawi Kamal	CFO and Corporate Secretary	Mar 04 '24	Sale	1.91	12,784	24,407	243,749	Mar 06 04:05 PM
Adawi Kamal	CFO and Corporate Secretary	Feb 06 '24	Sale	1.95	6,738	13,133	181,533	Feb 08 04:05 PM
ABALLI JOHN	President and CEO	Oct 17 '23	Sale	1.75	33,819	59,018	415,984	Oct 18 04:05 PM
TULLIS JAMES L L	10% Owner	Jun 15 '23	Buy	3.11	167	519	1,515,839	Jun 20 05:04 PM

Open in Screener

PSNL

Personalis Inc

May 03 • 04:00PM ET

1.54

Dollar change -0.06
Percentage change -3.75	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKG VTI VXF IWC AVSC DFAS

Index	-	P/E	-	EPS (ttm)	-2.25	Insider Own	17.70%	Shs Outstand	50.48M	Perf Week	21.74%
Market Cap	77.77M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-0.14%	Shs Float	41.56M	Perf Month	10.00%
Income	-108.30M	PEG	-	EPS next Q	-0.41	Inst Own	40.30%	Short Float	2.58%	Perf Quarter	16.67%
Sales	73.48M	P/S	1.06	EPS this Y	29.83%	Inst Trans	-3.30%	Short Ratio	3.33	Perf Half Y	61.43%
Book/sh	2.56	P/B	0.60	EPS next Y	12.03%	ROA	-41.83%	Short Interest	1.07M	Perf Year	-36.36%
Cash/sh	2.26	P/C	0.68	EPS next 5Y	-13.70%	ROE	-62.31%	52W Range	0.89 - 2.60	Perf YTD	-26.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.46%	ROI	-64.08%	52W High	-40.77%	Beta	1.91
Dividend TTM	-	Quick Ratio	2.88	Sales past 5Y	18.20%	Gross Margin	24.78%	52W Low	72.92%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	3.00	EPS Y/Y TTM	9.27%	Oper. Margin	-131.05%	RSI (14)	59.32	Volatility	13.15% 8.15%
Employees	225	Debt/Eq	0.38	Sales Y/Y TTM	12.97%	Profit Margin	-147.38%	Recom	1.33	Target Price	4.60
Option/Short	Yes / Yes	LT Debt/Eq	0.31	EPS Q/Q	20.18%	Payout	-	Rel Volume	1.10	Prev Close	1.60
Sales Surprise	0.24%	EPS Surprise	-8.00%	Sales Q/Q	17.66%	Earnings	May 08 AMC	Avg Volume	322.61K	Price	1.54
SMA20	14.46%	SMA50	5.49%	SMA200	3.27%	Trades		Volume	355,557	Change	-3.75%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-23	Upgrade	Needham	Hold → Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy	$27 → $23
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy	$33 → $28
May-06-21	Upgrade	Oppenheimer	Perform → Outperform	$28
Jan-28-21	Initiated	Truist	Buy	$50
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral	$40
Nov-12-20	Reiterated	Needham	Buy	$25 → $32
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy	$35
Oct-08-20	Initiated	BTIG Research	Buy	$35
Aug-27-20	Initiated	H.C. Wainwright	Buy	$30
Aug-18-20	Initiated	Needham	Buy	$25
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy	$22
Jul-15-19	Initiated	Oppenheimer	Outperform	$29
Jul-15-19	Initiated	Morgan Stanley	Overweight	$28
Jul-15-19	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-24-24 04:01PM	Personalis to Announce First Quarter 2024 Financial Results (Business Wire) -5.80%
Mar-28-24 04:01PM	Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
09:00AM	Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-26-24 09:00AM	Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring (Business Wire)
Mar-19-24 04:43PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:44AM	Loading…
Feb-29-24 09:44AM	Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.16%
Feb-28-24 05:00PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-14-24 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Jan-31-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
Jan-30-24 09:00AM	Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology (Business Wire) -8.50%
Jan-17-24 04:15PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.06%
Jan-16-24 09:05AM	Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay (Business Wire) -5.17%
Jan-05-24 09:05AM	Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance (Business Wire) +7.00%
Dec-04-23 09:15AM	Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives (Business Wire) +6.80%
04:15PM	Loading…
Nov-28-23 04:15PM	Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing (Business Wire) -8.33%
Nov-16-23 04:05PM	Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers (GlobeNewswire) -7.21%
03:03PM	Meet the biotech company Cathie Wood bought half a million shares of this month (TheStreet.com)
Nov-08-23 01:45PM	Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript (Insider Monkey) +21.52%
Nov-07-23 04:50PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance) -9.17%
04:01PM	Personalis Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 08:15AM	Personalis Launches NeXT Personal Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer (Business Wire)
Oct-24-23 04:01PM	Personalis to Announce Third Quarter 2023 Financial Results (Business Wire) +15.04%
Oct-21-23 04:25AM	Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology (Business Wire)
Oct-19-23 07:15AM	Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023 (Business Wire)
Oct-18-23 07:15AM	Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance (Business Wire)
Aug-29-23 04:01PM	Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference (Business Wire) +7.95%
Aug-24-23 07:01PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.41%
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-08-23 05:40PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Loading…
04:32PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
Jul-25-23 04:01PM	Personalis to Announce Second Quarter 2023 Financial Results (Business Wire)
Jul-13-23 06:51AM	Personalis (NASDAQ:PSNL) adds US$23m to market cap in the past 7 days, though investors from three years ago are still down 86% (Simply Wall St.)
Jun-26-23 05:00PM	Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics (Business Wire)
Jun-13-23 07:01PM	Dr. Kenneth J. Widder Joins Personalis Board of Directors (Business Wire)
Jun-08-23 10:49AM	Not Many Are Piling Into Personalis, Inc. (NASDAQ:PSNL) Just Yet (Simply Wall St.)
May-30-23 08:00AM	Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023 (Business Wire) -6.22%
May-16-23 08:00AM	Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer (Business Wire) -6.36%
May-07-23 03:07PM	Personalis, Inc. (NASDAQ:PSNL) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-05-23 12:03PM	Companies Like Personalis (NASDAQ:PSNL) Could Be Quite Risky (Simply Wall St.)
May-04-23 01:03PM	Q1 2023 Personalis Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:45PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.00%
04:37PM	Personalis: Q1 Earnings Snapshot (AP Finance)
04:01PM	Personalis Reports First Quarter 2023 Financial Results (Business Wire)
May-02-23 08:00AM	Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer (Business Wire) -5.17%
Apr-19-23 04:01PM	Personalis to Announce First Quarter 2023 Financial Results (Business Wire)
Apr-08-23 08:10AM	Personalis, Inc. (NASDAQ:PSNL) is favoured by institutional owners who hold 62% of the company (Simply Wall St.)
Apr-05-23 04:01PM	Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference (Business Wire)
08:45AM	Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study (Business Wire)
Mar-22-23 08:55AM	Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023 (Business Wire)
Mar-07-23 08:55AM	Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay (Business Wire)
Mar-02-23 04:05PM	Personalis Appoints Christopher Hall as Chief Executive Officer (Business Wire)
Feb-28-23 12:00PM	Personalis (PSNL) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-26-23 07:31AM	Personalis Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Feb-24-23 01:32PM	Q4 2022 Personalis Inc Earnings Call (Thomson Reuters StreetEvents) -7.23%
Feb-23-23 04:01PM	Personalis Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-09-23 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-07-23 10:07AM	15 Worst Stock Picks of Cathie Wood in 2022 (Insider Monkey) +7.47%
Feb-06-23 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
01:41PM	Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down (Benzinga)
Feb-03-23 12:38PM	Why Personalis Shares Are Trading Higher Today (Benzinga) +28.29%
08:45AM	Personalis and Moderna Sign New Agreement to Leverage NeXT Platform in Personalized mRNA Cancer Vaccine Clinical Trials (Business Wire)
Jan-19-23 10:17AM	Fremont cancer test business Personalis to cut staff by one-third (American City Business Journals) -9.43%
04:31AM	Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce (Benzinga)
Jan-05-23 05:21AM	Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of one-year loss (Simply Wall St.)
Jan-04-23 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue (Business Wire) +8.46%
Dec-16-22 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.52%
Dec-14-22 04:02PM	Personalis Announces CEO Retirement and Transition (Business Wire)
Nov-30-22 08:55AM	Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer (Business Wire) +9.96%
Nov-21-22 04:01PM	Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-07-22 04:05PM	Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Business Wire) -8.30%
02:16PM	Here's Why Personalis (NASDAQ:PSNL) Must Use Its Cash Wisely (Simply Wall St.)
Nov-02-22 05:15PM	Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Personalis Reports Third Quarter 2022 Financial Results (Business Wire)
Oct-31-22 04:16PM	Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business (Business Wire)
Oct-19-22 04:01PM	Personalis to Announce Third Quarter 2022 Financial Results (Business Wire) -10.31%
Oct-11-22 01:45PM	Personalis, Inc.'s (NASDAQ:PSNL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures (Simply Wall St.)
Oct-04-22 09:00AM	Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer (Business Wire) +8.33%
Aug-30-22 04:01PM	Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire) -6.88%
Aug-17-22 04:15PM	Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics (Business Wire) -6.08%
Aug-16-22 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.34%
Aug-15-22 08:55AM	Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers (Business Wire)
Aug-08-22 12:26PM	Is Personalis (NASDAQ:PSNL) Using Debt Sensibly? (Simply Wall St.) -8.87%
Aug-04-22 04:01PM	Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference (Business Wire)
Aug-03-22 05:35PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.07%
04:01PM	Personalis Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-02-22 04:10PM	Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics (Business Wire) +11.51%
Jul-20-22 04:01PM	Personalis to Announce Second Quarter 2022 Financial Results (Business Wire) +6.97%
Jul-12-22 04:05PM	Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease (Business Wire)
Jun-09-22 06:54AM	Strong week for Personalis (NASDAQ:PSNL) shareholders doesn't alleviate pain of one-year loss (Simply Wall St.)
May-04-22 06:05PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Personalis Reports First Quarter 2022 Financial Results (Business Wire)
01:44PM	What Is The Ownership Structure Like For Personalis, Inc. (NASDAQ:PSNL)? (Simply Wall St.)
Apr-28-22 04:01PM	Personalis to Present at Upcoming Investor Conferences (Business Wire)
Apr-26-22 08:45AM	Evaxion to Utilize Personalis ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma (Business Wire) -6.81%
Apr-21-22 09:00AM	Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales (Business Wire) -9.39%
Apr-20-22 04:01PM	Personalis to Announce First Quarter 2022 Financial Results (Business Wire)
Apr-18-22 09:15AM	Cathie Woods Portfolio: 10 Stocks Under $10 (Insider Monkey)

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moore Stephen Michael	SVP and Chief Legal Officer	Apr 30 '24	Sale	1.37	4,523	6,197	72,397	May 02 05:52 PM
MYERS WOODROW A JR	Director	Mar 01 '24	Buy	1.67	10,000	16,700	26,116	Mar 05 05:15 PM
Tachibana Aaron	CFO AND COO	Jan 29 '24	Sale	1.37	716	981	184,521	Jan 31 04:27 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jan 29 '24	Sale	1.37	526	721	128,870	Jan 31 04:30 PM
Tachibana Aaron	CFO and COO	Dec 15 '23	Sale	1.47	6,747	9,918	185,237	Dec 19 06:07 PM
Chen Richard	Chief Medical Officer and EVP	Dec 15 '23	Sale	1.47	4,708	6,921	129,396	Dec 19 06:09 PM
Moore Stephen Michael	General Counsel	Dec 15 '23	Sale	1.47	1,476	2,170	76,920	Dec 19 06:02 PM
Moore Stephen Michael	General Counsel	Nov 16 '23	Sale	1.04	1,722	1,791	78,396	Nov 20 04:30 PM
Tachibana Aaron	CFO and COO	Nov 16 '23	Sale	1.04	1,344	1,398	191,984	Nov 20 04:30 PM
Chen Richard	Chief Medical Officer and EVP	Nov 16 '23	Sale	1.04	940	978	124,104	Nov 20 04:30 PM
Hall Christopher M	President and CEO	Nov 01 '23	Sale	0.93	20,459	19,027	204,541	Nov 03 09:00 PM
Tachibana Aaron	CFO and COO	Jul 31 '23	Sale	2.26	662	1,496	193,328	Aug 02 04:21 PM
Chen Richard	Chief Medical Officer and EVP	Jul 31 '23	Sale	2.26	485	1,096	125,044	Aug 02 04:20 PM
Tachibana Aaron	CFO and COO	Jun 16 '23	Sale	2.07	6,904	14,291	193,990	Jun 21 04:49 PM
Chen Richard	Chief Medical Officer and EVP	Jun 16 '23	Sale	2.07	4,817	9,971	125,529	Jun 21 04:51 PM
Moore Stephen Michael	General Counsel	Jun 16 '23	Sale	2.07	1,509	3,124	80,118	Jun 21 04:52 PM
Moore Stephen Michael	General Counsel	May 17 '23	Sale	1.98	1,781	3,526	81,627	May 19 05:39 PM
Tachibana Aaron	CFO and COO	May 17 '23	Sale	1.98	1,389	2,750	200,894	May 19 05:42 PM
Chen Richard	Chief Medical Officer and EVP	May 17 '23	Sale	1.98	971	1,923	130,346	May 19 05:37 PM

Open in Screener

DGX

Quest Diagnostics, Inc.

May 03 • 04:00PM ET

137.38

Dollar change +1.04
Percentage change 0.76	%

Healthcare • Diagnostics & Research • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

DGX Quest Diagnostics, Inc. daily Stock Chart

Held by: VTI VOO VO IVV VTV RSP VOE VIG SPLV USMV

Index	S&P 500	P/E	18.49	EPS (ttm)	7.43	Insider Own	0.45%	Shs Outstand	111.00M	Perf Week	2.32%
Market Cap	15.26B	Forward P/E	14.52	EPS next Y	9.46	Insider Trans	-3.49%	Shs Float	110.60M	Perf Month	4.47%
Income	842.00M	PEG	3.72	EPS next Q	2.34	Inst Own	90.89%	Short Float	2.73%	Perf Quarter	9.90%
Sales	9.29B	P/S	1.64	EPS this Y	1.33%	Inst Trans	-1.34%	Short Ratio	2.94	Perf Half Y	3.66%
Book/sh	57.95	P/B	2.37	EPS next Y	7.22%	ROA	6.30%	Short Interest	3.02M	Perf Year	0.59%
Cash/sh	4.27	P/C	32.20	EPS next 5Y	4.96%	ROE	13.49%	52W Range	119.59 - 145.58	Perf YTD	-0.36%
Dividend Est.	2.89 (2.10%)	P/FCF	16.12	EPS past 5Y	7.36%	ROI	7.85%	52W High	-5.63%	Beta	0.89
Dividend TTM	2.88 (2.10%)	Quick Ratio	0.89	Sales past 5Y	4.86%	Gross Margin	31.88%	52W Low	14.88%	ATR (14)	2.98
Dividend Ex-Date	Apr 05, 2024	Current Ratio	0.97	EPS Y/Y TTM	9.66%	Oper. Margin	14.48%	RSI (14)	60.19	Volatility	2.45% 2.09%
Employees	48000	Debt/Eq	0.83	Sales Y/Y TTM	-3.29%	Profit Margin	9.07%	Recom	2.40	Target Price	147.24
Option/Short	Yes / Yes	LT Debt/Eq	0.67	EPS Q/Q	-3.13%	Payout	37.76%	Rel Volume	0.62	Prev Close	136.34
Sales Surprise	3.46%	EPS Surprise	9.94%	Sales Q/Q	1.50%	Earnings	Apr 23 BMO	Avg Volume	1.03M	Price	137.38
SMA20	3.82%	SMA50	5.70%	SMA200	4.75%	Trades		Volume	640,496	Change	0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-26-24	Initiated	Leerink Partners	Market Perform	$135
Feb-07-24	Upgrade	Jefferies	Hold → Buy	$140 → $155
Jan-03-24	Initiated	Barclays	Equal Weight	$145
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy	$140 → $160
Jun-29-23	Initiated	Piper Sandler	Neutral
May-02-23	Downgrade	BofA Securities	Buy → Neutral	$166 → $148
Apr-03-23	Upgrade	Citigroup	Sell → Neutral	$125 → $142
Jan-23-23	Initiated	Evercore ISI	In-line	$159
Nov-17-22	Downgrade	Citigroup	Neutral → Sell	$145 → $125
Aug-22-22	Resumed	Morgan Stanley	Equal-Weight	$142
Apr-04-22	Downgrade	Citigroup	Buy → Neutral	$175 → $140
Feb-23-22	Downgrade	UBS	Buy → Neutral	$160 → $139
Feb-02-22	Downgrade	Jefferies	Buy → Hold	$135
Jan-28-22	Downgrade	Deutsche Bank	Buy → Hold	$190 → $129
May-04-21	Upgrade	UBS	Neutral → Buy	$135 → $158
Mar-12-21	Downgrade	Robert W. Baird	Outperform → Neutral	$137
Oct-21-20	Upgrade	Argus	Hold → Buy
Jul-29-20	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$144
Jul-14-20	Upgrade	BofA Securities	Neutral → Buy	$142
Jun-09-20	Upgrade	Wells Fargo	Underweight → Equal Weight	$90 → $120

Show Previous Ratings

May-02-24 10:42AM	Reasons to Retain Quest Diagnostics (DGX) Stock for Now (Zacks)
09:02AM	Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics (Zacks)
08:10AM	Quest Supports Expansion of Community Center and Provides No-Cost Wellness Testing to Newark Faith Community (ACCESSWIRE)
01:23AM	Quest to ramp up AI capabilities with purchase of PathAIs diagnostic lab (MedTech Dive)
May-01-24 10:44AM	Quest Diagnostics to Acquire PathAI Diagnostics Assets in Collaboration Deal (MT Newswires)
06:57AM	Loading…
06:57AM	Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI (PR Newswire)
Apr-30-24 08:37AM	Baird Adjusts Quest Diagnostics' Price Target to $144 From $138 (MT Newswires)
Apr-26-24 08:45AM	Quest Diagnostics Foundation and Green Bronx Machine Expand Collaboration to Bring Acclaimed Indoor Gardening Curriculum to More Communities and Raise Awareness for Impact of Nutrition Education on Health Equity (ACCESSWIRE)
01:05AM	Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight (GuruFocus.com)
Apr-25-24 11:13AM	Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-24-24 03:02AM	Quest Diagnostics Inc (DGX) Q1 2024 Earnings Call Transcript Highlights: Key Financial Outcomes ... (GuruFocus.com)
Apr-23-24 10:35PM	Q1 2024 Quest Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents) +5.08%
09:58PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
10:52AM	DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:54AM	Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down (Zacks)
08:01AM	Loading…
08:01AM	Quest Diagnostics Q1 2024 Earnings: Aligns with Analyst EPS Projections, Raises Full-Year Guidance (GuruFocus.com)
07:55AM	Quest Diagnostics Posts Flat Q1 Adjusted Earnings, Revenue Rises; 2024 Earnings, Revenue Guidance Raised (MT Newswires)
07:55AM	Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates (Zacks)
06:52AM	Quest Diagnostics: Q1 Earnings Snapshot (Associated Press Finance)
06:45AM	Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 (PR Newswire)
Apr-22-24 09:16AM	Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics (Zacks)
07:53AM	Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease (PR Newswire)
Apr-16-24 10:00AM	Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline (Zacks)
Apr-15-24 09:47AM	Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store? (Zacks)
09:15AM	Q4HE Initiative Recognized for Efforts To Reduce Health Disparities (ACCESSWIRE)
Apr-09-24 12:00PM	My Quest Story - Jessica Clow (ACCESSWIRE)
Apr-04-24 07:05AM	Quest Diagnostics Inc's Dividend Analysis (GuruFocus.com)
Apr-03-24 11:22AM	Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs (Zacks)
Apr-02-24 07:57AM	Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay (PR Newswire)
Apr-01-24 02:30PM	My Quest Story - Pauline Chaves (ACCESSWIRE)
12:30PM	Loading…
Mar-26-24 12:30PM	She Is Not Skipping a Beat, and Patients Are Noticing (ACCESSWIRE)
07:09AM	Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease (PR Newswire)
Mar-20-24 11:15AM	My Quest Story - Eddy Hurst (ACCESSWIRE)
Mar-19-24 03:06PM	Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024 (PR Newswire)
Mar-14-24 01:20PM	Quest Colleague Is Exhibiting Care for Every Patient in Her Chair (ACCESSWIRE)
Mar-06-24 01:45PM	Phlebotomist's Actions Keep One Patient Coming Back (ACCESSWIRE)
Mar-05-24 12:15PM	My Quest Story - Allan Mendez (ACCESSWIRE)
Mar-04-24 02:45PM	First PFAS 'Forever Chemicals' Consumer-Initiated Blood Test With Physician Consult Launches on questhealth.com (ACCESSWIRE)
Mar-01-24 09:36AM	Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition (Zacks)
Feb-29-24 01:45PM	On Rare Disease Day, Q4HE Collaboration Highlights Purpose in Action (ACCESSWIRE)
Feb-27-24 02:30PM	Ten Years Running: FORTUNE Names Quest Diagnostics One of 2024 'World's Most Admired Companies' (ACCESSWIRE)
12:19PM	Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity (Zacks)
Feb-24-24 12:06AM	Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight (GuruFocus.com)
Feb-23-24 11:24PM	Quest Diagnostics Inc Director Vicky Gregg Sells 2,500 Shares (GuruFocus.com)
11:30AM	Living Our Purpose - Ivelisse Lugo (ACCESSWIRE)
09:35AM	Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference (PR Newswire)
Feb-21-24 12:00PM	Quest Diagnostics and Instacart Collaborate To Reduce Food Insecurity Across the United States With Integrated Patient Health Coaching and Nutritious Grocery Delivery (ACCESSWIRE)
Feb-15-24 07:58AM	Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test (Zacks)
06:00AM	Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection (PR Newswire)
Feb-13-24 08:16AM	Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering (Zacks)
08:07AM	Quest Diagnostics Debuts MelaNodal Predict Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery (PR Newswire)
Feb-12-24 08:01AM	First PFAS 'Forever Chemicals' Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com (PR Newswire)
Feb-06-24 07:14AM	Reasons to Retain Quest Diagnostics (DGX) Stock for Now (Zacks)
Feb-05-24 07:17PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
Feb-02-24 10:10AM	Quest Diagnostics Incorporated (NYSE:DGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-01-24 10:56PM	Q4 2023 Quest Diagnostics Inc Earnings Call (Thomson Reuters StreetEvents)
06:06PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
12:58PM	Quest Diagnostics Inc (DGX) Reports Mixed 2023 Results and Sets Positive Outlook for 2024 (GuruFocus.com)
09:30AM	Quest Diagnostics (DGX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:27AM	Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down (Zacks)
07:55AM	Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:11AM	Quest Diagnostics: Q4 Earnings Snapshot (Associated Press Finance)
06:45AM	Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share (PR Newswire)
Jan-31-24 02:50PM	Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 'World's Most Admired Companies' (PR Newswire)
Jan-29-24 12:45PM	Fitbit and Quest Diagnostics Collaborate To Advance Research on the Use of Wearable Devices To Improve Metabolic Health (ACCESSWIRE)
Jan-26-24 04:07PM	Analyst Report: Quest Diagnostics Incorporated (Morningstar Research)
09:15AM	Quest Diagnostics (DGX) Advances in Cancer Research With New Deal (Zacks)
Jan-22-24 08:07AM	Haystack Oncology, developer of Haystack MRD, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma (PR Newswire)
Jan-19-24 07:25AM	Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study (Zacks)
Jan-18-24 07:18AM	Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store? (Zacks)
05:04AM	The Top 3 Stocks in the High-Potential Cancer Testing Market (InvestorPlace)
Jan-17-24 09:35AM	Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024 (PR Newswire)
08:58AM	Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health (PR Newswire)
Jan-15-24 07:46AM	Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics (Zacks)
05:02AM	Quest Diagnostics Inc's Dividend Analysis (GuruFocus.com)
Jan-10-24 09:40AM	Is Quest Diagnostics (DGX) Stock Undervalued Right Now? (Zacks)
Jan-09-24 01:01PM	Quest Diagnostics (DGX) to Boost Lab Services With New Buyout (Zacks)
08:05AM	Quest Diagnostics and Ultima Collaborate to Scale Ultimas Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing (Business Wire)
Jan-08-24 08:56AM	Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System (PR Newswire)
07:07AM	Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD technology in phase II clinical trial for unresectable stage III NSCLC (PR Newswire)
Jan-04-24 10:00AM	No-Cost Testing Helps Bolster I-HEAL Community Wellness Day in Mississippi Delta Region (ACCESSWIRE)
Jan-03-24 01:45PM	Reasons to Retain Quest Diagnostics (DGX) Stock for Now (Zacks)
Dec-21-23 01:04PM	Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-20-23 07:34AM	Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer (PR Newswire)
07:01AM	Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel (Zacks)
Dec-19-23 10:45AM	Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis (ACCESSWIRE)
08:54AM	Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel (PR Newswire)
Dec-18-23 10:30AM	Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundations Corporate Equality Index for Seventh Consecutive Year (ACCESSWIRE)
07:47AM	Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal (Zacks)
Dec-14-23 08:53AM	Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD in Clinical Study of Early-Stage Triple-Negative Breast Cancer (PR Newswire)
Dec-13-23 03:15PM	Quest Diagnostics Multi-Pronged Approach to Waste Reduction (ACCESSWIRE)
Dec-11-23 10:15AM	New Report From Quest Diagnostics Unveils Priorities for Community Health Centers (ACCESSWIRE)
Dec-08-23 07:25AM	Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden (Zacks)
Dec-07-23 01:50PM	Universal DX Announces Strategic Collaboration With Quest Diagnostics To Bring Advanced Colorectal Cancer Screening Blood Test to Patients and Providers in the United States (ACCESSWIRE)
08:01AM	Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States (PR Newswire)
Dec-06-23 09:04AM	Quest Diagnostics Receives Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index for Seventh Consecutive Year (PR Newswire)
Dec-05-23 02:30PM	ISO Standardization & Climate Action at Quest Diagnostics (ACCESSWIRE)
Dec-01-23 03:10PM	Whats Ahead for Data (The Wall Street Journal)
Nov-30-23 07:28AM	Reasons to Retain Quest Diagnostics (DGX) Stock for Now (Zacks)
Nov-29-23 11:33AM	Quest Diagnostics' (DGX) New Pact to Scale Precision Medicine (Zacks)

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KUPPUSAMY KARTHIK	SVP, Clinical Solutions	Apr 29 '24	Sale	140.00	1,760	246,400	13,435	May 01 04:26 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Feb 29 '24	Sale	125.88	5,611	706,313	38,478	Mar 01 04:50 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 29 '24	Sale	125.88	1,187	149,420	68,412	Mar 01 04:51 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 28 '24	Sale	126.57	5,557	703,349	69,599	Mar 01 04:51 PM
Gregg Vicky B	Director	Feb 23 '24	Sale	126.64	2,500	316,596	16,329	Feb 23 04:34 PM
Doherty Catherine T.	EVP, Regional Businesses	Feb 22 '24	Sale	126.14	821	103,561	70,800	Feb 23 04:32 PM
PREVOZNIK MICHAEL E	SVP & General Counsel	Feb 22 '24	Sale	126.14	661	83,379	40,206	Feb 23 04:35 PM

Open in Screener

CELC

Celcuity Inc

May 03 • 04:00PM ET

17.67

Dollar change +0.01
Percentage change 0.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF DWAS IWN VTWO IWC VTWV RYLD IWV

Index	RUT	P/E	-	EPS (ttm)	-2.70	Insider Own	32.17%	Shs Outstand	25.51M	Perf Week	10.99%
Market Cap	538.05M	Forward P/E	-	EPS next Y	-3.23	Insider Trans	-0.27%	Shs Float	20.66M	Perf Month	-11.21%
Income	-63.78M	PEG	-	EPS next Q	-0.70	Inst Own	42.35%	Short Float	8.94%	Perf Quarter	14.22%
Sales	0.00M	P/S	-	EPS this Y	-5.51%	Inst Trans	5.92%	Short Ratio	7.85	Perf Half Y	75.30%
Book/sh	5.48	P/B	3.22	EPS next Y	-13.68%	ROA	-34.76%	Short Interest	1.85M	Perf Year	82.82%
Cash/sh	5.93	P/C	2.98	EPS next 5Y	29.00%	ROE	-46.63%	52W Range	8.39 - 22.19	Perf YTD	21.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.52%	ROI	-36.03%	52W High	-20.36%	Beta	0.85
Dividend TTM	-	Quick Ratio	13.43	Sales past 5Y	0.00%	Gross Margin	-	52W Low	110.63%	ATR (14)	0.95
Dividend Ex-Date	-	Current Ratio	13.43	EPS Y/Y TTM	-3.24%	Oper. Margin	0.00%	RSI (14)	52.04	Volatility	5.98% 5.01%
Employees	55	Debt/Eq	0.27	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	25.75
Option/Short	Yes / Yes	LT Debt/Eq	0.27	EPS Q/Q	4.98%	Payout	-	Rel Volume	1.21	Prev Close	17.66
Sales Surprise	-	EPS Surprise	10.75%	Sales Q/Q	-	Earnings	Mar 27 AMC	Avg Volume	235.18K	Price	17.67
SMA20	0.40%	SMA50	-0.45%	SMA200	31.97%	Trades		Volume	284,562	Change	0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-22-24	Initiated	Stifel	Buy	$40
Dec-08-23	Initiated	H.C. Wainwright	Buy	$27
Oct-08-21	Initiated	Canaccord Genuity	Buy	$50
Sep-07-21	Initiated	Jefferies	Buy	$48
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy	$50
Jan-28-21	Reiterated	H.C. Wainwright	Buy	$14 → $18
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$11 → $14
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy	$36

May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-04-24 07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
Apr-01-24 01:38PM	Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 06:51AM	Q4 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) +18.94%
Mar-27-24 08:53PM	CELC Stock Earnings: Celcuity Beats EPS for Q4 2023 (InvestorPlace)
05:51PM	Loading…
05:51PM	Celcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key Developments (GuruFocus.com)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-21-24 11:17AM	Why Celcuity (CELC) Might Surprise This Earnings Season (Zacks)
Mar-20-24 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Mar-06-24 07:05AM	Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-28-24 07:05AM	Celcuity to Participate in Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 04:05PM	Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Feb-20-24 07:05AM	Celcuity Appoints Eldon Mayer as Chief Commercial Officer (GlobeNewswire) -5.51%
Dec-06-23 08:30AM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-01-23 11:02AM	Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
08:05AM	Loading…
Nov-22-23 08:05AM	Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 10:50AM	Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.10%
Nov-13-23 09:41PM	Q3 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
10:54AM	Celcuity Inc (CELC) Reports Q3 2023 Financial Results and Strategic Developments (GuruFocus.com)
07:05AM	Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-06-23 07:30AM	Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Nov-01-23 07:05AM	Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire) -5.35%
Oct-18-23 09:15AM	Celcuity Inc. Announces $50 Million Private Placement (ACCESSWIRE) +11.38%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-07-23 04:05PM	Celcuity to Host Virtual Science Day for Investors (GlobeNewswire)
Sep-06-23 07:10PM	7 Short-Squeeze Stocks That Actually Might Make Sense (InvestorPlace)
Aug-22-23 04:05PM	Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial (GlobeNewswire)
04:01PM	Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Aug-11-23 05:58AM	Q2 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:04PM	Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:30AM	Loading…
Aug-03-23 07:30AM	Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-31-23 08:00AM	Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-27-23 06:51AM	Celcuity Inc. (NASDAQ:CELC) stock most popular amongst individual investors who own 23%, while private equity firms hold 22% (Simply Wall St.)
Jun-20-23 09:02AM	Celcuity Set to Join Russell 2000 and 3000 Indexes (ACCESSWIRE)
May-24-23 08:00AM	Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences (ACCESSWIRE)
07:59AM	Insiders of Celcuity Getting Good Value On Their US$1.6m Investment \ (Simply Wall St.)
May-16-23 06:26AM	Q1 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 04:00PM	Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates (ACCESSWIRE)
May-12-23 06:15AM	Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress (ACCESSWIRE)
May-08-23 05:30PM	Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call (ACCESSWIRE)
08:00AM	Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress (ACCESSWIRE)
Apr-18-23 01:30PM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 (ACCESSWIRE)
Apr-12-23 08:00AM	Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference (ACCESSWIRE)
Mar-27-23 02:43AM	Celcuity Inc. (NASDAQ:CELC) Q4 2022 Earnings Call Transcript (Insider Monkey) +13.56%
Mar-24-23 07:07AM	Q4 2022 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -5.47%
Mar-23-23 04:00PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-16-23 08:00AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Mar-15-23 07:35PM	Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 (ACCESSWIRE)
Mar-01-23 08:00AM	Celcuity to Participate in Cowen's 43rd Annual Health Care Conference (ACCESSWIRE)
Feb-17-23 05:07AM	While institutions own 25% of Celcuity Inc. (NASDAQ:CELC), individual investors are its largest shareholders with 58% ownership (Simply Wall St.)
Feb-16-23 08:00AM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium (ACCESSWIRE)
Dec-18-22 04:38AM	Insiders pour millions into these 3 stocks this is what makes them attractive buys (TipRanks)
Dec-15-22 05:59AM	Bullish insiders bet US$1.6m on Celcuity Inc. (NASDAQ:CELC) (Simply Wall St.)
Dec-12-22 07:30AM	Celcuity Closes $100 Million Private Placement (ACCESSWIRE) +11.62%
Dec-09-22 08:40AM	Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Dec-07-22 04:00PM	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer (ACCESSWIRE) -6.21%
Nov-22-22 07:30AM	Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium (ACCESSWIRE) -5.36%
Nov-10-22 04:30PM	Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference (ACCESSWIRE)
04:00PM	Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-03-22 08:50AM	Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Sep-14-22 09:00AM	Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors (ACCESSWIRE)
Aug-15-22 09:39AM	What Is The Ownership Structure Like For Celcuity Inc. (NASDAQ:CELC)? (Simply Wall St.)
Aug-11-22 04:00PM	Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-04-22 08:15AM	Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE) +5.66%
Aug-03-22 10:15AM	Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference (ACCESSWIRE) +10.74%
Jul-18-22 06:31PM	Celcuity stock soars after hours on breakthrough therapy designation for cancer drug (MarketWatch)
05:10PM	Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer (ACCESSWIRE)
Jun-15-22 09:55AM	Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet (Zacks) +5.38%
May-30-22 09:55AM	Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-26-22 07:30AM	Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences (ACCESSWIRE)
May-16-22 04:00PM	Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates (ACCESSWIRE) +5.79%
07:00AM	Celcuity Inc. Announces $100 Million Private Placement (ACCESSWIRE)
May-11-22 09:28AM	Celcuity (NASDAQ:CELC) Has Debt But No Earnings; Should You Worry? (Simply Wall St.) -17.53%
May-09-22 07:30AM	Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Apr-05-22 07:30AM	Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences (ACCESSWIRE) -7.22%
Mar-23-22 04:00PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates (ACCESSWIRE)
Mar-16-22 07:30AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Mar-02-22 07:30AM	Celcuity to Participate in the Cowen 42nd Annual Health Care Conference (ACCESSWIRE)
Mar-01-22 07:02AM	What Percentage Of Celcuity Inc. (NASDAQ:CELC) Shares Do Insiders Own? (Simply Wall St.)
Jan-18-22 12:39PM	FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity (Benzinga)
07:30AM	Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update (ACCESSWIRE)
Dec-10-21 09:30AM	Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Dec-02-21 08:30AM	Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Nov-29-21 05:00PM	Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development (ACCESSWIRE)
Nov-15-21 08:00AM	Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial (ACCESSWIRE)
Nov-09-21 05:30PM	Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences (ACCESSWIRE) -5.41%
Nov-08-21 04:00PM	Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Oct-29-21 09:00AM	Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Oct-18-21 04:09PM	Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases (Business Wire)
Oct-14-21 02:08PM	2 Cutting-Edge Biotech Stocks That Can Double in Value (Or More) (TipRanks)
Sep-02-21 07:42AM	Do Insiders Own Lots Of Shares In Celcuity Inc. (NASDAQ:CELC)? (Simply Wall St.)
Aug-09-21 04:00PM	Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-05-21 08:00AM	Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference (ACCESSWIRE)
Aug-02-21 07:30AM	Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast (ACCESSWIRE)
Jul-08-21 04:15PM	Celcuity to Participate in the William Blair Biotech Focus Conference (ACCESSWIRE)
Jun-30-21 09:06AM	Where Do Hedge Funds Stand On Celcuity Inc. (CELC)? (Insider Monkey)
Jun-29-21 11:11AM	Why Celcuity Stock Is Crashing Today (Motley Fool) -21.34%
Jun-28-21 11:30PM	Celcuity Announces Pricing of Follow-on Offering (ACCESSWIRE)
04:01PM	Celcuity Announces Launch of Follow-on Offering (ACCESSWIRE)
Jun-09-21 09:10AM	Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations (ACCESSWIRE)

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buller Richard E	Director	Apr 24 '24	Sale	17.06	350	5,971	7,731	Apr 26 04:55 PM
Buller Richard E	Director	Feb 21 '24	Sale	14.15	350	4,952	8,081	Feb 23 04:43 PM
Buller Richard E	Director	Dec 20 '23	Sale	14.37	350	5,030	8,431	Dec 22 04:09 PM
Dalvey David	Director	Dec 15 '23	Sale	14.57	2,940	42,847	225,000	Dec 18 04:43 PM
Dalvey David	Director	Dec 14 '23	Sale	14.75	5,000	73,752	227,940	Dec 18 04:43 PM
Dalvey David	Director	Dec 13 '23	Sale	14.50	5,000	72,500	232,940	Dec 14 06:05 PM
Dalvey David	Director	Dec 12 '23	Sale	14.61	2,060	30,089	237,940	Dec 14 06:05 PM
Dalvey David	Director	Dec 08 '23	Sale	15.00	5,000	75,000	240,000	Dec 11 04:19 PM
Dalvey David	Director	Dec 07 '23	Sale	14.85	5,000	74,250	245,000	Dec 11 04:19 PM
Furcht Leo	Director	Nov 28 '23	Option Exercise	1.60	250	400	10,500	Nov 30 04:12 PM
Buller Richard E	Director	Oct 25 '23	Sale	10.23	350	3,580	8,781	Oct 27 04:30 PM
Buller Richard E	Director	Aug 30 '23	Sale	9.28	350	3,248	9,131	Sep 01 04:07 PM
Buller Richard E	Director	Aug 23 '23	Sale	9.82	300	2,946	9,481	Aug 25 05:09 PM
Buller Richard E	Director	Jun 23 '23	Sale	11.79	300	3,537	9,781	Jun 27 04:11 PM
Buller Richard E	Director	May 23 '23	Sale	11.10	75	832	10,081	May 25 04:23 PM
Furcht Leo	Director	May 22 '23	Buy	10.32	10,000	103,187	10,250	May 24 04:32 PM
Buller Richard E	Director	May 22 '23	Sale	10.50	100	1,050	10,156	May 23 04:12 PM
Buller Richard E	Director	May 19 '23	Sale	9.85	250	2,462	10,256	May 23 04:12 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CSTL

NTRA

EXAS

LH

VCYT

SERA

GH

XGN

PSNL

DGX

CELC

Upgrade your FINVIZ experience